<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001983" GROUP_ID="MUSKEL" ID="699099092212200056" MERGED_FROM="" MODIFIED="2010-05-25 15:56:48 -0400" MODIFIED_BY="Michelle Foote" REVIEW_NO="C014-R" REVMAN_SUB_VERSION="5.0.24" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2010-05-25 15:56:48 -0400" MODIFIED_BY="Michelle Foote">
<TITLE>Calcitonin for preventing and treating corticosteroid-induced osteoporosis</TITLE>
<CONTACT>
<PERSON ID="14918" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Ann</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Cranney</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>ancranney@ohri.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Division of Rheumatology</DEPARTMENT>
<ORGANISATION>Ottawa Hospital</ORGANISATION>
<ADDRESS_1>1053 Carling Ave</ADDRESS_1>
<ADDRESS_2/>
<CITY>Ottawa</CITY>
<ZIP>K1Y 4E9</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>613-798-5555 ext: 16804</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2010-05-25 15:56:48 -0400" MODIFIED_BY="Michelle Foote">
<PERSON ID="14918" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Ann</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Cranney</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>ancranney@ohri.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Division of Rheumatology</DEPARTMENT>
<ORGANISATION>Ottawa Hospital</ORGANISATION>
<ADDRESS_1>1053 Carling Ave</ADDRESS_1>
<ADDRESS_2/>
<CITY>Ottawa</CITY>
<ZIP>K1Y 4E9</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>613-798-5555 ext: 16804</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="13312" ROLE="AUTHOR">
<PREFIX>Ms</PREFIX>
<FIRST_NAME>Vivian</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Welch</LAST_NAME>
<SUFFIX/>
<POSITION>Research Associate</POSITION>
<EMAIL_1>vivian.welch@uottawa.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Centre for Global Health, Institute of Population Health</DEPARTMENT>
<ORGANISATION>University of Ottawa</ORGANISATION>
<ADDRESS_1>1 Stewart Street, Room 206</ADDRESS_1>
<ADDRESS_2/>
<CITY>Ottawa</CITY>
<ZIP>K1N 6N5</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 613 562-5800 ext: 2921</PHONE_1>
<PHONE_2/>
<FAX_1>+1 613 562-5659</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="5185" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Jonathan</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Adachi</LAST_NAME>
<SUFFIX>MD, FRCP(C)</SUFFIX>
<POSITION/>
<EMAIL_1>jd.adachi@sympatico.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>St Joseph's Hospital</ORGANISATION>
<ADDRESS_1>25 Charlton Ave East - Suite 501</ADDRESS_1>
<ADDRESS_2/>
<CITY>Hamilton</CITY>
<ZIP>L8N 1Y2</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 905 529 1317</PHONE_1>
<PHONE_2/>
<FAX_1>+1 905 521 1297</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="5318" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Joanne</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Homik</LAST_NAME>
<SUFFIX/>
<POSITION>Assistant Clinical Professor of Medicine</POSITION>
<EMAIL_1>joanne.homik@ualberta.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Deparment of Medicine</DEPARTMENT>
<ORGANISATION>University of Alberta</ORGANISATION>
<ADDRESS_1>562 Heritage Medical Research Centre</ADDRESS_1>
<ADDRESS_2/>
<CITY>Edmonton</CITY>
<ZIP>T6G 2S2</ZIP>
<REGION>Alberta</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 780 407 8070</PHONE_1>
<PHONE_2/>
<FAX_1>+1 780 407 6055</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="5440" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Beverley</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Shea</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>bevshea@uottawa.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Institute of Population Health</DEPARTMENT>
<ORGANISATION>University of Ottawa</ORGANISATION>
<ADDRESS_1>1 Stewart St.</ADDRESS_1>
<ADDRESS_2>Room 312</ADDRESS_2>
<CITY>Ottawa</CITY>
<ZIP>K1N 6N5</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 613 562 5800 ext: 8571</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="15002" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Maria</FIRST_NAME>
<MIDDLE_INITIALS>E</MIDDLE_INITIALS>
<LAST_NAME>Suarez-Almazor</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>msalmazor@mdanderson.org</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>General Internal Medicine, Ambulatory Treatment and Emergency Care</DEPARTMENT>
<ORGANISATION>The University of Texas, M.D. Anderson Cancer Center</ORGANISATION>
<ADDRESS_1>1515 Holcombe Blvd</ADDRESS_1>
<ADDRESS_2>Unit 1465</ADDRESS_2>
<CITY>Houston</CITY>
<ZIP>77030</ZIP>
<REGION>Texas</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>1 713 745 4516</PHONE_1>
<PHONE_2/>
<FAX_1>1 713 563 4491</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="5474" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Peter</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Tugwell</LAST_NAME>
<SUFFIX/>
<POSITION>Director</POSITION>
<EMAIL_1>elacasse@uottawa.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Centre for Global Health, Institute of Population Health, Department of Medicine</DEPARTMENT>
<ORGANISATION>Ottawa Hospital</ORGANISATION>
<ADDRESS_1>1 Stewart Street</ADDRESS_1>
<ADDRESS_2/>
<CITY>Ottawa</CITY>
<ZIP>K1N 6N5</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>613-562-5800 ext: 1945</PHONE_1>
<PHONE_2/>
<FAX_1>613-562-5659</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="12662" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>George</FIRST_NAME>
<MIDDLE_INITIALS>A</MIDDLE_INITIALS>
<LAST_NAME>Wells</LAST_NAME>
<SUFFIX>PhD, MSc</SUFFIX>
<POSITION>Director</POSITION>
<EMAIL_1>gawells@ottawaheart.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cardiovascular Research Reference Centre</DEPARTMENT>
<ORGANISATION>University of Ottawa Heart Institute</ORGANISATION>
<ADDRESS_1>Room H1-1</ADDRESS_1>
<ADDRESS_2>40 Ruskin Street</ADDRESS_2>
<CITY>Ottawa</CITY>
<ZIP>K1Y 4W7</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 613 798 5555 x18640</PHONE_1>
<PHONE_2>+1 613 798 5555 x18642</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-05-27 22:28:40 -0400" MODIFIED_BY="Lara Maxwell">
<UP_TO_DATE>
<DATE DAY="27" MONTH="10" YEAR="1999"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="27" MONTH="10" YEAR="1999"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="1" YEAR="2004"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="" YEAR=""/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2000"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2000"/>
</DATES>
<WHATS_NEW MODIFIED="2008-05-27 22:29:09 -0400" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-05-27 22:29:09 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="28" MONTH="5" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format. CMSG ID C014-R</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-05-27 22:30:45 -0400" MODIFIED_BY="[Empty name]"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Loeb Research Institute, Clinical Epidemiology Unit</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-05-27 22:31:31 -0400" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-05-27 22:31:31 -0400" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-05-27 22:31:31 -0400" MODIFIED_BY="[Empty name]">Calcitonin for preventing and treating corticosteroid-induced osteoporosis</TITLE>
<SUMMARY_BODY>
<P>Long-term corticosteroids are prescribed for a number of reasons, including inflammatory bowel disease, chronic obstructive lung disease and rheumatoid arthritis. Steroids cause bone loss by a variety of complex mechanisms. Calcitonin is an anti-resorptive therapy that has been approved for the treatment of established osteoporosis. The purpose of this review was to evaluate calcitonin as a means of preventing bone loss with corticosteroid therapy. Nine randomized controlled trials were included in the review, with 221 patients randomized to calcitonin and 220 to placebo. The results showed that calcitonin prevents bone loss at the spine and forearm by about 3% after the first year of therapy. There was no effect on bone loss at the hip. Calcitonin was not statistically different from placebo at preventing fractures of the spine and long bones, such as hip fractures. Calcitonin was associated with four times the side effects of placebo, and these were mostly nausea and facial flushing. </P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Corticosteroid-induced osteoporosis is a cause of morbidity in patients with chronic obstructive lung disease, asthma, and rheumatologic disorders. Corticosteroid treatment causes bone loss by a variety of complex mechanisms. It has been shown that bone mineral loss at the hip averages 14% in the first year after starting corticosteroid therapy.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To review the efficacy of calcitonin (subcutaneous or nasal) for the treatment and prevention of corticosteroid-induced osteoporosis.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We conducted a search of Medline, the Cochrane Controlled Trials Register and Embase using the Cochrane Musculoskeletal Group search strategy for randomized controlled trials (RCTs) up to May 1998. We also searched bibliographic references and consulted content experts.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Two independent reviewers selected RCTs which met predetermined inclusion criteria.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two reviewers independently extracted data using predetermined forms and assessed methodological quality of randomization, blinding and dropouts. For dichotomous outcomes, relative risks (RR) were calculated. For continuous data, weighted mean differences (WMD) of the percent change from baseline were calculated. We decided a priori to use random effects models for all outcomes, because of uncertainty about whether a consistent true effect exists in such different populations.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Nine trials met the inclusion criteria, including 221 patients randomized to calcitonin and 220 to placebo. The median methodologic quality was two out of a maximum of five points. Calcitonin was more effective than placebo at preserving bone mass at the lumbar spine after six and 12 months of therapy with a WMD of 2.8% (95% CI: 1.4 to 4.3) and 3.2% (95% CI: 0.3 to 6.1). At 24 months, lumbar spine BMD was not statistically different between groups: WMD 4.5% (95% CI: -0.6 to 9.5)]. Bone density at the distal radius was also higher with calcitonin after six months of therapy, but bone density at the femoral neck was not different between placebo and calcitonin treated groups. The relative risk of fractures was not significantly different between calcitonin and placebo with a relative risk (RR) of 0.71 (95% CI: 0.26 to 1.89) for vertebral and 0.52 (95% CI: 0.14 to 1.96) for non vertebral fractures. The subgroup analyses of methodological quality and duration of corticosteroid therapy were confounded. Trials of patients who had been taking steroids for greater than three months (which were of low methodologic quality) demonstrated a larger effect of calcitonin on spine bone density (about 6%) than prevention trials (about 1%). There was no consistent effect of different dosages (50-100 IU compared to 200-400 IU). However, subcutaneous calcitonin showed substantially greater prevention of bone loss. Withdrawals due to side effects were higher in the calcitonin-treated groups: RR 3.19 (95%CI: 0.66 to 15.47). Important side effects included nausea and facial flushing.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Calcitonin appears to preserve bone mass in the first year of glucocorticoid therapy at the lumbar spine by about 3% compared to placebo, but not at the femoral neck. Our analysis suggests that the protective effect on bone mass may be greater for the treatment of patients who have been taking corticosteroids for more than three months. Efficacy of calcitonin for fracture prevention in steroid-induced osteoporosis remains to be established.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY>
<BACKGROUND>
<P>Osteoporosis and subsequent fracture are a major cause of morbidity and mortality. It is a disease state defined by low bone mass, and has many etiologies with different patterns of bone loss. Involutional or senile osteoporosis causes loss of both cortical and trabecular bone, whereas steroid-induced osteoporosis is associated with rapid rates of spinal bone loss (<LINK REF="REF-Adachi-1999" TYPE="REFERENCE">Adachi 1999</LINK>, <LINK REF="REF-Ruegsegger-1983" TYPE="REFERENCE">Ruegsegger 1983</LINK>). Because of this differential effect, vertebral collapse is the most common fracture in patients on steroids. Patients with inflammatory disorders such as rheumatoid arthritis, inflammatory bowel disease and sarcoidosis, are uniquely at risk for osteoporosis due to their underlying disease, as well as the frequent administration of corticosteroids.</P>
<P>A recent cohort study in the USA has identified that on average, 30-40% of rheumatoid arthritis patients are prescribed prednisone (<LINK REF="REF-Ward-1998" TYPE="REFERENCE">Ward 1998</LINK>). They are usually maintained on steroid therapy for a mean of four years. As for polymyalgia rheumatica (PMR), steroids are the accepted method of treatment with greater than 95% of patients being treated in this manner. Therapy for this disorder is usually continued for one to three years. Additionally, steroids are prescribed for patients with chronic obstructive lung disease, asthma and inflammatory bowel disease.</P>
<P>Corticosteroid therapy is a contributor to the development of osteoporosis in these populations. A prospective cohort study has shown that most of the bone loss occurs in the first 5-7 months of treatment (<LINK REF="REF-LoCasio-1984" TYPE="REFERENCE">LoCasio 1984</LINK>). Steroids cause bone loss by a variety of complex mechanisms (<LINK REF="REF-Manolagas-1999" TYPE="REFERENCE">Manolagas 1999</LINK>). They act to decrease absorption of calcium from the intestine, and increase urinary calcium loss. This leads to the development of secondary hyperparathyroidism, which results in bone resorption. Steroids may also directly inhibit osteoblasts from laying down new bone. Glucocorticoids suppress the hypthalmic-pituitary-gonadal axis which leads to functional hypogonadism (<LINK REF="REF-MacAdams-1998" TYPE="REFERENCE">MacAdams 1998</LINK>). Male rheumatoid arthritis patients on steroids have been shown to have lower testosterone levels, presumably on the basis of suppressed hypothalmic-pituitary-testicular axis (<LINK REF="REF-Adachi-1997R" TYPE="REFERENCE">Adachi 1997R</LINK>). </P>
<P>It has been shown in steroid treated sarcoid patients, that bone mineral loss at the hip averages 14% in the first year after starting corticosteroid therapy, and in steroid-treated, early post-menopausal women this figure increases to 22% (<LINK REF="REF-Montemurro-1990" TYPE="REFERENCE">Montemurro 1990</LINK>). One study has shown that even 5 mg of prednisone per day doubles the rate of bone loss in females and males over an eight year period (<LINK REF="REF-Saito-1995" TYPE="REFERENCE">Saito 1995</LINK>). It has been suggested that patients initiating steroids should receive therapy such as vitamin D, estrogens, calcitonin, fluoride or bisphosphonates (<LINK REF="REF-ACR-1996" TYPE="REFERENCE">ACR 1996</LINK>). Calcium should be considered as an adjunct to other agents (<LINK REF="REF-Adachi-1999" TYPE="REFERENCE">Adachi 1999</LINK>). It is not yet common practice for patients to receive osteoporosis prophylaxis at the time they begin steroid therapy. In a recent study of 147 patients receiving long-term oral corticosteroid therapy, 42% of postmenopausal women were receiving no preventive therapy (<LINK REF="REF-Buckley-1999" TYPE="REFERENCE">Buckley 1999</LINK>).</P>
</BACKGROUND>
<OBJECTIVES>
<P>To determine the efficacy of calcitonin in the prevention and treatment of steroid induced osteoporosis.</P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>All randomized controlled trials (RCTs) and controlled clinical trials (CCTs) meeting the inclusion criteria were included in this systematic review.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Men or women over the age of 18, with any underlying disease that requires therapy with systemic corticosteroids. Prevention was defined as initiating calcitonin therapy within three months of starting corticosteroid therapy. Treatment was defined by populations who were taking corticosteroids for at least three months prior to starting calcitonin therapy.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Randomized controlled clinical trials that used calcitonin for the prevention or treatment of steroid induced osteoporosis. We accepted control groups that received a placebo or were untreated. Calcium and vitamin D were accepted in the control group if they were also given in equal doses to the treated group.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>The primary outcomes assessed were percent change in bone mineral density at six months, one and two years. We also looked at reduction in vertebral and non vertebral fracture incidence. Toxicity was assessed by tabulating side effects, withdrawals due to adverse events and withdrawals overall.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>MEDLINE, EMBASE and the Cochrane Controlled Trials Register (CCTR) were used to identify all clinical trials relating to calcitonin treatment of steroid-induced osteoporosis. We used the MEDLINE search strategy adopted and modified for the Cochrane Musculoskeletal Group (<LINK REF="REF-Haynes-1994" TYPE="REFERENCE">Haynes 1994</LINK>), and search the years 1966 - August 1998. Keywords used for the search included: bone diseases, osteoporosis, anti-inflammatory agents;steroidal, corticosteroid and calcitonin. The search strategy is provided below.</P>
<P>Database: Medline &lt;1966 - 1995&gt;</P>
<P> Set Search Results<BR/> -------------------------------------------------------------<BR/> 1 exp steroids/ 349986<BR/> 2 steroid$.tw,rn. 73234<BR/> 3 methylprednisone.tw,sh. 59<BR/> 4 cortisol.tw,sh,tw. 19225<BR/> 5 prednisone.tw,sh,rn. 21935<BR/> 6 glucocorticoid.rn,tw,sh. 12798<BR/> 7 exp adrenal cortex hormones/ 111945<BR/> 8 exp cyclosporins/ 15453<BR/> 9 cyclosporin$.tw,sh,rn. 18712<BR/> 10 or/1-9 421180<BR/> 11 exp bone diseases, metabolic/ 18847<BR/> 12 osteoporos#s.tw. 8369<BR/> 13 bone density/ 5510<BR/> 14 bone densit$.tw. 2662<BR/> 15 bone mineral densit$.tw. 2234<BR/> 16 exp "bone and bones"/ 215705<BR/> 17 bone loss$.tw. 3564<BR/> 18 osteomalacia.tw. 2107<BR/> 19 osteodystrophy.tw. 1572<BR/> 20 exp bone demineralization, pathologic/ 252<BR/> 21 (bone adj demineralization).tw. 155<BR/> 22 osteopenia.tw. 1367<BR/> 23 bone mass.tw. 2622<BR/> 24 exp densitometry/ 11119<BR/> 25 densitometry.tw. 3064<BR/> 26 dexa.tw. 299<BR/> 27 exp fractures/ 60136<BR/> 28 fracture$.tw. 55676<BR/> 29 or/11-28 288564<BR/> 30 clinical trial.pt. 190918<BR/> 31 randomized controlled trial.pt. 85487<BR/> 32 tu.fs. 700826<BR/> 33 dt.fs. 637888<BR/> 34 random$.tw. 122317<BR/> 35 (double adj blind$).tw. 39767<BR/> 36 placebo$.tw. 43690<BR/> 37 or/30-36 993683<BR/> 38 10 and 29 10827<BR/> 39 calcitonin.sh,rn,tw. 13293<BR/> 40 (calcitrin or thyrocalcitonin).tw. 705<BR/> 41 miacalcin.tw. 1<BR/> 42 or/39-41 13337<BR/> 43 38 and 42 579<BR/> 44 37 and 43 260</P>
<P>Similar strategies were developed for searching EMBASE, although currently we were only able to search the years 1988 - 1996.</P>
<P>All foreign language journals were included in the search.</P>
<P>An electronic search in Current Contents was done for the last six months up to Sept 1, 1999.</P>
<P>The lists of references were manually searched to add any citations missed by the electronic searches. Abstracts from the following scientific meetings were manually checked and included if the information was available in the body of the abstract: American Society for Bone and Mineral Research, American College of Rheumatology, Canadian Rheumatology Association.</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>After fulfilling the initial criteria, the following criteria were also required:</P>
<P>Randomized allocation of patients into treatment groups. We looked for the words random and randomized in the methods of allocation of the trial and blinding of the study participants and investigators to the study group allocation.</P>
<P>We required an adequate description of the intervention medications in terms of dosage schedule and administration. We also required documentation of withdrawals and dropouts.</P>
<P>Methods used to collect data from included trials:</P>
<P>Data was extracted from the trials by two independent observers (AC,VW). Agreement between the two were assessed using the kappa statistic. In the case of disagreements, the two observers discussed the issue and attempted to reach a consensus. If necessary, a third observer was used as an adjudicator (BS). </P>
<P>Data was extracted for the following time points and outcomes:<BR/>Time Points:<BR/>Six months<BR/>One year<BR/>Two years</P>
<P>Outcomes:<BR/>Efficacy<BR/> Percent change in bone mineral density<BR/> Incidence of vertebral fractures<BR/> Incidence of non vertebral fractures<BR/>Toxicity<BR/> Number of patients with side-effects<BR/> Number of withdrawals due to side-effects<BR/> Withdrawals overall</P>
<P>Methods to synthesize data</P>
<P>All the trials were analyzed using Review Manager 4.0.3 and Metaview 3.1. For continuous variables such as bone density, we anticipated reports of mean differences. Thus, we did not calculate effect sizes. If absolute values were reported, we calculated mean differences. The mean difference for each intervention group was weighted by the sample size of the group. </P>
<P>Dichotomous results including fractures, dropouts and withdrawals were summarized as relative risks. The summary relative risk was obtained by weighting each individual relative risk by the inverse of the variance of the estimate for each trial. </P>
<P>The results for each trial were tested for heterogeneity using the chi square statistic.</P>
<P>We decided a priori to use random effects models throughout, due to the variety of patient populations and underlying diseases. We suspected that heterogeneity would be significant for most comparisons due to differences in the populations.</P>
<P>A sensitivity analysis was conducted to evaluate the robustness of the meta-analysis results. This analysis examined the effects of methodological quality, duration of steroid therapy (prevention versus treatment) and potential differences in drug dosage and administration. </P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>The literature searches retrieved 303 articles. One abstract was located by searching abstract books (<LINK REF="STD-Emkey-1995" TYPE="STUDY">Emkey 1995</LINK>). Of these articles, 12 were considered potential RCTs. Of these, nine randomized controlled trials were included (<LINK REF="STD-Adachi-1997" TYPE="STUDY">Adachi 1997</LINK>, <LINK REF="STD-Bohning-1990" TYPE="STUDY">Bohning 1990</LINK>, <LINK REF="STD-Emkey-1995" TYPE="STUDY">Emkey 1995</LINK>, <LINK REF="STD-Healey-1996" TYPE="STUDY">Healey 1996</LINK>, <LINK REF="STD-Kotaniemi-1996" TYPE="STUDY">Kotaniemi 1996</LINK>, <LINK REF="STD-Luengo-1990" TYPE="STUDY">Luengo 1990</LINK>, <LINK REF="STD-Luengo-1994" TYPE="STUDY">Luengo 1994</LINK>, <LINK REF="STD-Ringe-1987" TYPE="STUDY">Ringe 1987</LINK>, <LINK REF="STD-Sambrook-1993" TYPE="STUDY">Sambrook 1993</LINK>). Three trials were excluded due to lack of a placebo group (<LINK REF="STD-Garcia_x002d_Delgado-1997" TYPE="STUDY">Garcia-Delgado 1997</LINK>), retrospective cohort design (<LINK REF="STD-Montemurro-1991" TYPE="STUDY">Montemurro 1991</LINK>), and one trial included a rheumatoid arthritis population which was not treated with corticosteroids (<LINK REF="STD-Dottori-1982" TYPE="STUDY">Dottori 1982</LINK>).</P>
<P>The included trials involved 221 patients randomized to calcitonin and 220 to placebo.<BR/>Of the included trials, four involved populations with polymyalgia rheumatica, temporal arteritis or rheumatoid arthritis (<LINK REF="STD-Adachi-1997" TYPE="STUDY">Adachi 1997</LINK>, <LINK REF="STD-Healey-1996" TYPE="STUDY">Healey 1996</LINK>, <LINK REF="STD-Kotaniemi-1996" TYPE="STUDY">Kotaniemi 1996</LINK>, <LINK REF="STD-Sambrook-1993" TYPE="STUDY">Sambrook 1993</LINK>), two involved patients with chronic obstructive lung disease (COPD) (<LINK REF="STD-Bohning-1990" TYPE="STUDY">Bohning 1990</LINK>, <LINK REF="STD-Ringe-1987" TYPE="STUDY">Ringe 1987</LINK>) two involved asthmatic populations (<LINK REF="STD-Luengo-1994" TYPE="STUDY">Luengo 1994</LINK>, <LINK REF="STD-Luengo-1990" TYPE="STUDY">Luengo 1990</LINK>), and one did not specify the indication for steroids (<LINK REF="STD-Emkey-1995" TYPE="STUDY">Emkey 1995</LINK>).</P>
<P>Subcutaneous calcitonin was given in three trials (<LINK REF="STD-Healey-1996" TYPE="STUDY">Healey 1996</LINK>, <LINK REF="STD-Ringe-1987" TYPE="STUDY">Ringe 1987</LINK>, <LINK REF="STD-Luengo-1990" TYPE="STUDY">Luengo 1990</LINK>). </P>
<P>Four trials were classified as prevention trials, defined by initiation of calcitonin therapy within three months of starting corticosteroid therapy (<LINK REF="STD-Adachi-1997" TYPE="STUDY">Adachi 1997</LINK>, <LINK REF="STD-Healey-1996" TYPE="STUDY">Healey 1996</LINK>, <LINK REF="STD-Kotaniemi-1996" TYPE="STUDY">Kotaniemi 1996</LINK>, <LINK REF="STD-Sambrook-1993" TYPE="STUDY">Sambrook 1993</LINK>). The other trials were categorized as treatment trials because the patients had taken chronic steroids for greater than 3 months prior to initiating calcitonin therapy (<LINK REF="STD-Bohning-1990" TYPE="STUDY">Bohning 1990</LINK>, <LINK REF="STD-Luengo-1990" TYPE="STUDY">Luengo 1990</LINK>, <LINK REF="STD-Luengo-1994" TYPE="STUDY">Luengo 1994</LINK>, <LINK REF="STD-Emkey-1995" TYPE="STUDY">Emkey 1995</LINK>, <LINK REF="STD-Ringe-1987" TYPE="STUDY">Ringe 1987</LINK>).</P>
<P>Two authors were contacted in July 1999 for further information (<LINK REF="STD-Emkey-1995" TYPE="STUDY">Emkey 1995</LINK>, <LINK REF="STD-Kotaniemi-1996" TYPE="STUDY">Kotaniemi 1996</LINK>), but no replies have been received as yet.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>Quality was assessed using a validated, five point scale which included items relating to randomization (two points), blinding (two points), and description of withdrawals and dropouts (one point) (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>). Two reviewers reached consensus on the scores (AC, VW).</P>
<P>The median quality score was two. One trial scored one point, four trials scored two points, two trials scored three points and one trial scored four points.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>Bone density<BR/>Heterogeneity was significant for most outcomes, confirming our a priori decision to use random effects models.</P>
<P>Bone density at the lumbar spine was increased relative to placebo at all time points from six to 24 months: six months WMD: 2.8% (95% CI: 1.4 to 4.3), 12 months WMD: 3.2% (95% CI: 0.3 to 6.1) and 24 months WMD: 4.5% (95% CI: -0.6 to 9.5). At the femoral neck, no difference was observed between treated and placebo groups at six, 12 or 24 months. At the distal radius, bone density was increased at six and 12 months with WMD of 2.9% (95%CI: 1.4 to 4.4) and 3.1% (95%CI: -0.6 to 6.7) respectively, but not at 24 months.</P>
<P>Fractures</P>
<P>Vertebral fractures were reported in five trials, which included 127 patients randomized to calcitonin and 129 to placebo (<LINK REF="STD-Healey-1996" TYPE="STUDY">Healey 1996</LINK>, <LINK REF="STD-Kotaniemi-1996" TYPE="STUDY">Kotaniemi 1996</LINK>, <LINK REF="STD-Luengo-1994" TYPE="STUDY">Luengo 1994</LINK>, <LINK REF="STD-Ringe-1987" TYPE="STUDY">Ringe 1987</LINK>, <LINK REF="STD-Sambrook-1993" TYPE="STUDY">Sambrook 1993</LINK>). The relative risk of vertebral fracture was reduced with calcitonin, but not significantly: RR 0.71 (95% CI: 0.26 to 1.89). Heterogeneity was not significant (chi-square 2.61, df 4). An analysis of evaluable patients only (efficacy) found no difference in treatment effect.</P>
<P>The relative risk of non vertebral fractures was not statistically significant in the four trials with 102 patients randomized to calcitonin and 106 to placebo (RR 0.52, 95% CI: 0.14 to 1.96). Heterogeneity was not significant (chi square 2.23, df 3).</P>
<P>Toxicity</P>
<P>There was no difference in overall withdrawals, but withdrawals due to side effects was higher in the calcitonin group, though not statistically significant (RR 3.19, 95%CI: 0.66 to 15.47). Reported side effects that were increased in the calcitonin group relative to control were flushing or rashes (RR 5.0, 95% CI: 1.36 to 18.42) and nausea (RR 8.65, 95%CI: 1.61 to 46.54). Gastrointestinal symptoms, nasal symptoms and hypercalcemia were not different between calcitonin and placebo.</P>
<P>Sensitivity analysis</P>
<P>Methodological quality<BR/>Low quality trials (less than three on Jadad's scale) showed a greater risk reduction for vertebral fractures (RR: 0.50, 95% CI: 0.12 to 2.06 compared to RR 0.91, 95% CI: 0.23 to 3.60), but the relative risk reduction was still not significant. Low quality trials also found a greater difference in lumbar bone density at 12 months (WMD 6.1, 95% CI: 4.5 to 7.8 compared to WMD 0.9, 95% CI: -1.9 to 3.7). However, this analysis was confounded since all of the low quality trials involved treatment populations who were already taking corticosteroids for greater than three months prior to starting calcitonin. </P>
<P>Dose of calcitonin<BR/>No consistent differences in effect were observed for the different dosage categories used.</P>
<P>Route of administration of calcitonin (subcutaneous versus intranasal)<BR/>Subcutaneous injection of calcitonin was used in one trial that reported bone density and it showed the greatest difference in lumbar bone density (WMD 6.5%, 95%CI: 4.6 to 8.4) (<LINK REF="STD-Luengo-1990" TYPE="STUDY">Luengo 1990</LINK>). One trial with subcutaneous injection showed a greater vertebral fracture risk reduction (RR 0.14, 95% CI: 0.01 to 2.59) (<LINK REF="STD-Ringe-1987" TYPE="STUDY">Ringe 1987</LINK>) than the four trials that used nasal calcitonin. However, this risk reduction was not significant.</P>
<P>Prevention versus Treatment<BR/>As described above, this subgroup analysis was confounded since all of the prevention trials were of high quality (greater than or equal to three on Jadad's scale). However, the results suggest that there is a differential effect of calcitonin on prevention of bone loss in patients initiating steroid therapy (WMD spine: 0.9, 95%CI: -1.9 to 3.7) compared to those who have been treated for more than three months with steroids (WMD spine: 6.1, 95%CI: 4.5 to 7.8). </P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>Calcitonin has been approved by the FDA and the Health Protection Board (Canada) as an alternate therapy for the treatment of patients with established postmenopausal osteoporosis. Bisphosphonates and combinations of calcium and vitamin D have proven efficacy for the prevention of bone loss for patients with steroid-induced osteoporosis (<LINK REF="REF-Homik-1999b" TYPE="REFERENCE">Homik 1999b</LINK>, <LINK REF="REF-Amin-1999" TYPE="REFERENCE">Amin 1999</LINK>, <LINK REF="REF-Homik-1999a" TYPE="REFERENCE">Homik 1999a</LINK>).</P>
<P>The recent PROOF trial demonstrated that calcitonin prevents vertebral fractures in women with post-menopausal osteoporosis (<LINK REF="REF-Chesnut-1998" TYPE="REFERENCE">Chesnut 1998</LINK>). However, there was a large withdrawal rate from this trial (of approximately 30%), which raises concerns about generalizability.</P>
<P>The results of this meta-analysis show that calcitonin prevents bone loss, as measured by bone density at the spine and distal radius, but not at the femoral neck. We found a non-significant reduced relative risk for both vertebral and non vertebral fractures. The toxicity analysis demonstrated that calcitonin was associated with significantly more patient self-reports of flushing and nausea. </P>
<P>All of these trials had small sample sizes (less than 40 per group). This sample size is insufficient to detect some evidence for fracture prevention, even with statistical pooling of several trials. The sample size required to detect a difference in vertebral fracture prevention is probably greater than 200, especially considering the mixed populations in these trials (<LINK REF="REF-Cranney-1999" TYPE="REFERENCE">Cranney 1999</LINK>). The sample size required is lower in populations with prevalent vertebral fractures.</P>
<P>We used random effects models for all analyses because of concern about significant heterogeneity of results. The random effects model incorporates variation in treatment effect between trials, and results in wider, more conservative confidence intervals. </P>
<P>Low quality trials have been shown to overestimate the treatment effect for a variety of different interventions and populations (<LINK REF="REF-Moher-1998" TYPE="REFERENCE">Moher 1998</LINK>). In our analysis, low methodological quality trials showed a greater protective effect of calcitonin on bone density. However, these low quality trials all involved treatment populations (patients who were taking corticosteroids for greater than three months prior to starting calcitonin). Therefore, it is not possible to determine from this analysis whether the quality or the population characteristics are responsible for the observed difference in treatment effect. The treatment trials (which were all of low quality) found a 6% difference in spine bone density between calcitonin and control at 12 months. The prevention trials (which were all of high quality) found a nonsignificant difference of only 1% in 12 months spine bone density.</P>
<P>There was no dose-response effect with calcitonin. However, the trial that used subcutaneous injections showed the greatest difference in bone density between treated and control groups. This may be due to greater bio-availability of the drug when given by the subcutaneous route (<LINK REF="REF-Adachi-1997R" TYPE="REFERENCE">Adachi 1997R</LINK>).</P>
<P>In conclusion, calcitonin has not yet demonstrated effectiveness at preventing fractures associated with steroid-induced osteoporosis. However, calcitonin appears to prevent bone loss at the lumbar spine by about 3% in the first year. The beneficial effect of calcitonin on bone density may be greater in patients who have been taking corticosteroids for more than three months. Longer term trials, with an adequate sample size, are necessary to confirm whether calcitonin continues to preserve bone mass beyond one year and whether calcition has a significant effect on fractures. The evidence from this meta-analysis suggests that calcitonin can be considered as an alternative treatment for corticosteroid induced osteoporosis, particularly for patients who have been taking corticosteroids for greater than 3 months.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Therapies with proven fracture efficacy, such as bisphosphonates, should remain the first line treatment for patients at risk of steroid-induced osteoporosis, until further research becomes available.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>A large scale randomized controlled trial is necessary to determine whether calcitonin can prevent vertebral and non vertebral fractures in this population.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>The authors would like to thank Jessie McGowan for help with the electronic search strategy and the Cochrane Musculoskeletal Review Group Editorial Team and the Osteoporosis Facilitators for their time and effort reviewing this document. A special thanks to Norma and Jim Davies and Jacqueline Tetroe for their comments and helpful suggestions.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>AC, VW and JDA are responsible for the content, protocol and interpretation of results. GW assisted with the statistical analysis. BS, PT, JH, MES helped with the protocol development and commented on draft versions of the review. BS, PT and GW helped with the development of the extraction forms and quality assessment forms.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Adachi-1997" NAME="Adachi 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Adachi JD, Bensen WG, Bell MJ, et al. Salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis.&lt;br&gt;Br J Rheumatol 1997;36:255-59.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Adachi JD, Bensen WG, Bell MJ, et al</AU>
<TI>Salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis</TI>
<SO>Br J Rheumatol</SO>
<YR>1997</YR>
<VL>36</VL>
<PG>255-59</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bohning-1990" NAME="Bohning 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Bohning W, Ringe JD, Weizel D, Bode V. Intranasales lachscalcitonin zur prophylaxe des knochenmineralverlustes bei steroid-bedurftigen, chronisch-obstruktiven atemwegserkrankungen. Drug Res 1990; 40: 1000-1003.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bohning W, Ringe JD, Weizel D, Bode V</AU>
<TI>Intranasales lachscalcitonin zur prophylaxe des knochenmineralverlustes bei steroid-bedurftigen, chronisch-obstruktiven atemwegserkrankungen</TI>
<SO>Drug Res</SO>
<YR>1990</YR>
<VL>40</VL>
<PG>1000-1003</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Emkey-1995" NAME="Emkey 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Emkey R, Reading W, Procaccini R, Gaich G and Steroid Induced Osteoporosis Study Group</AU>
<TI>The Effect of calcitonin on bone mass in steroid-induced osteoporosis</TI>
<SO>Arthr Rheum</SO>
<YR>1994</YR>
<VL>37</VL>
<NO>9</NO>
<PG>S183</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Healey-1996" NAME="Healey 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Healey JH, Paget SA, Williams-Russo P, et al. a randomized controlled of salmon calcitonin to prevent bone loss in corticosteroid-trated temporal arteritis and polymyalgia rheumatica.&lt;br&gt;Calcif Tissue Int 1996; 58:73-80.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Healey JH, Paget SA, Williams-Russo P, et al</AU>
<TI>a randomized controlled of salmon calcitonin to prevent bone loss in corticosteroid-trated temporal arteritis and polymyalgia rheumatica</TI>
<SO>Calcif Tissue Int</SO>
<YR>1996</YR>
<VL>58</VL>
<PG>73-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kotaniemi-1996" NAME="Kotaniemi 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Kotaniemi A, Piirainen H, Paimela L, et al. Is continuous intranasal salmon calcitonin effective in treating axial bone loss in pateints with active rheumatoid arthritis receiving low dose glucocorticoid therapy? J Rheumatol 1996; 23:1875-9.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kotaniemi A, Piirainen H, Paimela L, et al</AU>
<TI>Is continuous intranasal salmon calcitonin effective in treating axial bone loss in pateints with active rheumatoid arthritis receiving low dose glucocorticoid therapy?</TI>
<SO>J Rheumatol</SO>
<YR>1996</YR>
<VL>23</VL>
<PG>1875-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Luengo-1990" NAME="Luengo 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Luengo m, Picado C, Del Rio l, Guanabens, Montserrat JM, Setoain J. Treatment of steroid-induced osteopenia with calcitonin in corticosteroid- dependent asthma. Am Rev Resp 1990'; 142:104-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luengo M, Picado C, Del Rio L, Guanabens N, Montserrat JM, Setoain J</AU>
<TI>Treatment of steroid-induced osteopenia with calcitonin in corticosteroid- dependent asthma</TI>
<SO>Am Rev Resp</SO>
<YR>1990'</YR>
<VL>142</VL>
<PG>104-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Luengo-1994" NAME="Luengo 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Luengo Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoiod therapy for asthma: a two year follow up study. Thorax 1994; 49:1099-1102.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luengo M, Pons F, Martinez de Osaba MJ, Picado C.</AU>
<TI>Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoiod therapy for asthma: a two year follow up study</TI>
<SO>Thorax</SO>
<YR>1994</YR>
<VL>49</VL>
<NO>11</NO>
<PG>1099-1102</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="95132992"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ringe-1987" NAME="Ringe 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;Ringe JD, Welzel D. Salmon calcitonin in the therapy of corticoid-induced osteoporosis. Eur J Clin Pharmacol 1987; 33:35-9.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ringe JD, Welzel D</AU>
<TI>Salmon calcitonin in the therapy of corticoid-induced osteoporosis</TI>
<SO>Eur J Clin Pharmacol</SO>
<YR>1987</YR>
<VL>33</VL>
<PG>35-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sambrook-1993" NAME="Sambrook 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Sambrook P, Birmingham J, Kelly P, et al. Prevention of corticosteroid-induced osteoporosis. NEJM 1993; 328 (24): 1747-52.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sambrook P, Birmingham J, Kelly P, et al</AU>
<TI>Prevention of corticosteroid-induced osteoporosis</TI>
<SO>NEJM</SO>
<YR>1993</YR>
<VL>328</VL>
<NO>24</NO>
<PG>1747-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Dottori-1982" NAME="Dottori 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;[Calcifediol and calcitonin in the therapy of rheumatoid arthritis. A short-term controlled study]. [Italian]. 73 (43):3033-3040, 1982.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dottori L, D'Ottavio D, Brundisini B</AU>
<TI>Calcifediol and calcitonin in the therapy of rheumatoid arthritis. A short-term controlled study</TI>
<SO>Minerva Medica</SO>
<YR>1982</YR>
<VL>73</VL>
<NO>43</NO>
<PG>3033-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="83063449"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garcia_x002d_Delgado-1997" NAME="Garcia-Delgado 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Garcia-Delgado I, Prieto S, Gil-Fraguas L, Robles E, Rufolanchas JJ, Hawkins F. Calcitonin, etidronate, and calcidiol treatment in bone loss after cardiac transplantation. Calcif Tissue Int 1997; 60: 155-159.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garcia-Delgado I, Prieto S, Gil-Fraguas L, Robles E, Rufolanchas JJ, Hawkins F</AU>
<TI>Calcitonin, etidronate, and calcidiol treatment in bone loss after cardiac transplantation</TI>
<SO>Calcif Tissue Int</SO>
<YR>1997</YR>
<VL>60</VL>
<PG>155-159</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Montemurro-1991" NAME="Montemurro 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Montemurro L, Schiraldi G, Fraioli P, Tosi G, Riboldi A, Rizzato G. Prevention of corticosteroid-induced osteoporosis with salmon calcitonin in sarcoid patients. Calcif Tissue Int 1991; 49: 71-6.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Montemurro L, Schiraldi G, Fraioli P, Tosi G, Riboldi A, Rizzato G</AU>
<TI>Prevention of corticosteroid-induced osteoporosis with salmon calcitonin in sarcoid patients</TI>
<SO>Calcif Tissue Int</SO>
<YR>1991</YR>
<VL>49</VL>
<PG>71-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-ACR-1996" NAME="ACR 1996" NOTES="&lt;p&gt;Anonymous. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. American College of Rheumatology Task Force on Osteoporosis Guidelines. Arthritis &amp;amp; Rheum 39 (11):1791-1801, 1996.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. American College of Rheumatology Task Force on Osteoporosis Guidelines</TI>
<SO>Arthritis &amp; Rheum</SO>
<YR>1996</YR>
<VL>39</VL>
<NO>11</NO>
<PG>1791-1801</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Adachi-1997R" NAME="Adachi 1997R" NOTES="&lt;p&gt;Adachi JD. Corticosteroid-induced osteoporosis. Am J Med Sci 1997; 313 (1):41-49.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Adachi JD</AU>
<TI>Corticosteroid-induced osteoporosis</TI>
<SO>Am J Med Sci</SO>
<YR>1997</YR>
<VL>313</VL>
<NO>1</NO>
<PG>41-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Adachi-1999" NAME="Adachi 1999" TYPE="JOURNAL_ARTICLE">
<AU>Adachi JD, Rostom A</AU>
<TI>Metabolic bone disease in adults with inflammatory bowel disease</TI>
<SO>Inflamm Bowel Dis</SO>
<YR>1999</YR>
<VL>5</VL>
<NO>3</NO>
<PG>200-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Adachi-1999b" NAME="Adachi 1999b" TYPE="JOURNAL_ARTICLE">
<AU>Adachi JD, Ioannidis G</AU>
<TI>Calcium and vitamin D therapy in corticosteroid-induced bone loss: what is the evidence?</TI>
<SO>Calcif Tissue Int</SO>
<YR>1999</YR>
<VL>65</VL>
<NO>4</NO>
<PG>335-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Amin-1999" NAME="Amin 1999" TYPE="JOURNAL_ARTICLE">
<AU>Amin S, LaValley MP, Simms RW, Felson DT</AU>
<TI>The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach</TI>
<SO>Arthritis Rheum</SO>
<YR>1999</YR>
<VL>42</VL>
<NO>8</NO>
<PG>1740-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Buckley-1999" NAME="Buckley 1999" TYPE="JOURNAL_ARTICLE">
<AU>Buckley LM, Marquez M, Feezor R, Ruffin DM, Benson LL</AU>
<TI>Prevention of corticosteroid-induced osteoporosis: results of a patient survey</TI>
<SO>Arthritis Rheum</SO>
<YR>1999</YR>
<VL>42</VL>
<NO>8</NO>
<PG>1736-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chesnut-1998" NAME="Chesnut 1998" TYPE="JOURNAL_ARTICLE">
<AU>Chestnut C, Silverman SL, Andriano K, et al</AU>
<TI>Salmon calcitonin nasal spray reduces the rate of new vertebral fractures independently of known major pre-treatment risk factors: accrued five year analysis of the PROOF study</TI>
<SO>J Bone Mineral Research</SO>
<YR>1998</YR>
<VL>8</VL>
<PG>S290</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cranney-1999" NAME="Cranney 1999" TYPE="JOURNAL_ARTICLE">
<AU>Cranney A, Welch V, Tugwell P, Wells G, Adachi JD, McGowan J, Shea B.</AU>
<TI>Responsiveness of endpoints in osteoporosis clinical trials - an update</TI>
<SO>J Rheumatol</SO>
<YR>1999</YR>
<VL>26</VL>
<NO>1</NO>
<PG>222-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Haynes-1994" NAME="Haynes 1994" NOTES="&lt;p&gt;Haynes RB, Wilczynski N, McKibbon KA, Walker CJ, Sinclair JC. Developing optimal search strategies for detecting clinically sound studies in MEDLINE. J Am Med Informatics Assoc 1994; 1: 447-58.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Haynes RB, Wilczynski N, McKibbon KA, Walker CJ, Sinclair JC</AU>
<TI>Developing optimal search strategies for detecting clinically sound studies in MEDLINE</TI>
<SO>J Am Med Informatics Assoc</SO>
<YR>1994</YR>
<VL>1</VL>
<PG>447-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Homik-1999a" NAME="Homik 1999a" NOTES="&lt;p&gt;Homik J, Suarez-Almazor ME, Shea B, et al. Calcium and vitamin D for corticosteroid-induced osteoporosis (Cochrane Review). IN The Cochrane Library, Issue 1, 1999. Oxford: Update Software.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Homik J, Suarez-Almazor ME, Shea B, et al</AU>
<TI>Calcium and vitamin D for corticosteroid-induced osteoporosis (Cochrane Review). IN The Cochrane Library, Issue 1, 1999</TI>
<PG>Update Software</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Homik-1999b" NAME="Homik 1999b" NOTES="&lt;p&gt;Homik J, Cranney A, Shea B, et al. Bisphosphonates for steroid induced osteoporosis (Cochrane Review). IN The Cochrane Library, Issue 1, 1999. Oxford: Update Software.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Homik J, Cranney A, Shea B, et al</AU>
<TI>Bisphosphonates for steroid induced osteoporosis (Cochrane Review). IN The Cochrane Library, Issue 1, 1999</TI>
<PG>Update Software</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" NAME="Jadad 1996" NOTES="&lt;p&gt;Jadad A, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clinical Trials 1996; 17: 1-12.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Jadad A, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ et al</AU>
<TI>Assessing the quality of reports of randomized clinical trials: is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-LoCasio-1984" NAME="LoCasio 1984" NOTES="&lt;p&gt;LoCasio V, Bonucci E, Imbimbo B, et al. Bone loss after glucocorticoid therapy. Calcif Tissue Int 1984; 36: 435.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>LoCasio V, Bonucci E, Imbimbo B, et al</AU>
<TI>Bone loss after glucocorticoid therapy</TI>
<SO>Calcif Tissue Int</SO>
<YR>1984</YR>
<VL>36</VL>
<PG>435</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-MacAdams-1998" NAME="MacAdams 1998" NOTES="&lt;p&gt;Macadams MR. Reduction in serum testerone levels during chronic glucorticoid therapy. White RH, Chipps BE. Ann Intern Med 104, 648-51. 1998.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Macadams MR</AU>
<TI>Reduction in serum testerone levels during chronic glucorticoid therapy. White RH, Chipps BE. Ann Intern Med 104, 648-51</TI>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Manolagas-1999" NAME="Manolagas 1999" NOTES="&lt;p&gt;Manolagas SC, Weinstein RS. New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res 1999; 14 (7): 1061-6.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Manolagas SC, Weinstein RS</AU>
<TI>New developments in the pathogenesis and treatment of steroid-induced osteoporosis</TI>
<SO>J Bone Miner Res</SO>
<YR>1999</YR>
<VL>14</VL>
<NO>7</NO>
<PG>1061-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-1998" NAME="Moher 1998" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P, Klassen TP</AU>
<TI>Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<NO>9128</NO>
<PG>609-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Montemurro-1990" NAME="Montemurro 1990" NOTES="&lt;p&gt;Montemurro L, Fraioli P, Riboldi A, Delpiano S, Zanni D, Rizzato G. Bone loss in prednisone treated sarcoidosis: a two year follow-up. Annali Italiani di Medicina Interna 1990; 5(3 Pt 1): 164-8.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Montemurro L, Fraioli P, Riboldi A, Delpiano S, Zanni D, Rizzato G</AU>
<TI>Bone loss in prednisone treated sarcoidosis: a two year follow-up</TI>
<SO>Annali Italiani di Medicina Interna</SO>
<YR>1990</YR>
<VL>5</VL>
<NO>3 Pt 1</NO>
<PG>164-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ruegsegger-1983" NAME="Ruegsegger 1983" TYPE="JOURNAL_ARTICLE">
<AU>Ruegsegger P, Boiseau VC, Avioli</AU>
<TI>Corticosteroid-induced bone loss. A longitudinal study of alternate day therapy in patients with bronchial asthma using quantitative computer tomography. Eur J Clin Pharmacol</TI>
<YR>1983</YR>
<VL>25</VL>
<PG>615-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Saito-1995" NAME="Saito 1995" TYPE="JOURNAL_ARTICLE">
<AU>Saito JK, Davis JW, Wasnich RC, Ross PD</AU>
<TI>Users of low dose glucocorticoids have increased bone loss rates: a longitudinal study</TI>
<SO>Calcif Tissue Int</SO>
<YR>1995</YR>
<VL>57</VL>
<PG>115-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ward-1998" NAME="Ward 1998" NOTES="&lt;p&gt;Ward MM, Fries JF. Trends in antirheumatic medication use among patients with rheumatoid arthritis, 1981-1996. J Rheumatol 1998; 25(3):408-16.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Ward MM, Fries JF</AU>
<TI>Trends in antirheumatic medication use among patients with rheumatoid arthritis, 1981-1996</TI>
<SO>J Rheumatol</SO>
<YR>1998</YR>
<VL>25</VL>
<NO>3</NO>
<PG>408-16</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Adachi-1997">
<CHAR_METHODS>
<P>Double blind, minimized, placebo controlled trial;<BR/>Prevention<BR/>Sample size at entry: SCT 16; placebo 15<BR/>Withdrawals: SCT 4; Placebo 2<BR/>Trial duration: 12 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Polymyalgia rheumatica with or without temporal arteritis, over 50 years of age, started prednisone within 1 month at does &gt; 10 mg/d<BR/>Mean age: 71 years<BR/>Women/Men: SCT 9/7; Placebo 9/6<BR/>Prednisone dose: 17.2 mg/d<BR/>Lumbar spine (mg/cm2): SCT 1.06; Placebo: 1.11</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Intranasal salmon calcitonin, 200 IU daily</P>
<P>Calcium supplemented if baseline calcium intake &lt; 800 mg/d</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>DXA lumbar spine, femoral neck, trochanter, Total body, withdrawals</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score = 4 <BR/>(R 1, B 2, W 1)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Bohning-1990">
<CHAR_METHODS>
<P>Randomized, double-blind trial<BR/>Treatment<BR/>Trial duration: 12 months<BR/>Sample size at entry: 36<BR/>Withdrawals: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Chronic obstructive lung disease with permanent steroid intake of at least 2 years previously with a mean dose of 10 mg/d prednisone<BR/>Age: 56 (44-67)<BR/>Men/Women: 26/10<BR/>Mean prednisone dose: 16 mg (12.5 to 25)<BR/>Mean prednisone duration: 6 years (2-12)<BR/>Lumbar bone mineral content (g/cm): SCT 3.44; Placebo: 3.61 <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Intranasal Salmon Calcitonin 200 IU/day<BR/>vs Placebo nasal spray<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Bone mineral content at spine and forearm (g/cm), spinal deformity index, biochemical markers</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality = 2<BR/>(R 1, B 1, W 0)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Emkey-1995">
<CHAR_METHODS>
<P>Randomized, double blind, controlled trial<BR/>Treatment<BR/>Sample size at entry: 75<BR/>Withdrawals: 19<BR/>Trial duration: 6 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Patients taking average daily dose of at least 10 mg prednisone for 3 months prior to study entry<BR/>Age range: 24-70 years<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Calcitonin 50 IU by subcutaneous injection versus placebo</P>
<P>Both groups received calcium to bring total intake to 1500 mg/d and vitamin D 400 IU/d</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>DEXA lumbar spine, SPA forearm BMC</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality = not applicable- abstract</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Healey-1996">
<CHAR_METHODS>
<P>Randomized, controlled, double blind trial<BR/>Prevention<BR/>Sample size at entry: SCT 25; Pl 23<BR/>Withdrawals: SCT 6; Pl 2<BR/>Trial duration: 24 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>48 patients with newly diagnosed temporal arteritis, PMR<BR/>Mean age: SCT 71.6; Pl 71.7 years<BR/>Women/Men: SCT 16/9; Pl 20/3<BR/>Cumulative dose steroid: SCT 5371 mg; Pl 4680 mg<BR/>Lumbar BMD(g/cm2): SCT 1.008 (0.212); Pl 0.987 (0.227)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Subcutaneous calcitonin 100 IU every other day versus<BR/>Placebo injections</P>
<P>Both groups received calcium 1500 mg/d + Vitamin D3 400 IU</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>DXA Lumbar spine, Femoral neck BMD, vertebral fractures</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score = 3 <BR/>(R 1, B 1, W 1)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kotaniemi-1996">
<CHAR_METHODS>
<P>Randomized, open parallel<BR/>Prevention<BR/>Sample size at entry: SCT 32; Placebo 31<BR/>Withdrawals: SCT 6; Placebo 8<BR/>Trial duration: 12 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Participants with RA (ACR criteria), using glucocorticoids &gt; 7.5 mg/d prednisolone ordered for &gt; 3 months<BR/>Mean age: 49.2 years<BR/>Number postmenopausal: SCT 15; Placebo 19<BR/>Lumbar BMD (g/cm2): SCT 1.036; Placebo 1.023</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Intranasal calcitonin 100 IU/day (Miacalcin) versus untreated</P>
<P>500 mg Calcium in both groups</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>BMD spine, femoral neck, trochanter, vertebral fractures, nonvertebral fractures, side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score =2 <BR/>(R 1, B 0, W 1)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Luengo-1990">
<CHAR_METHODS>
<P>Randomized, open, controlled trial<BR/>Treatment<BR/>Sample size at entry: SCT 31; Ca 31<BR/>Withdrawals: SCT 11; Ca none, but only 20 used in analysis<BR/>Trial duration: 12 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>62 steroid dependent asthmatics who had received steroids for at least 1 year<BR/>Mean age: SCT 58.9; Pl 60.1 years<BR/>Women/Men: SCT 8/12; Pl 8/12<BR/>Prednisone dose: SCT 10.5; Pl 10.9 mg/day<BR/>Lumbar spine BMD, g/cm2: SCT 0.89 ; Pl 1.03<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Subcutaneous salmon calcitonin 100 IU every other day versus untreated</P>
<P>Both groups received Calcium 1 g/d<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Lunar DPA Lumbar spine, side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score = 1 <BR/>(R 0, B 0, W 1)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Luengo-1994">
<CHAR_METHODS>
<P>Randomized, open parallel trial<BR/>Treatment<BR/>Sample size at entry: SCT 22; Ca 22<BR/>Withdrawals: SCT 5; Ca 5<BR/>Trial duration: 24 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Asthma, steroid dependent patients, received steroids for at least 1 year<BR/>Mean age: 58.9 years<BR/>Dose prednisone: 10 mg/d<BR/>Duration steroid treatment: 9.7 years<BR/>Women/Men: SCT 19/3; Ca 19/3<BR/>Prevalent fractures: SCT 4/22; Ca 4/22 <BR/>Lumbar BMD (% predicted): SCT 88; Ca 91</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Intranasal calcitonin 200 IU q 2 days versus untreated</P>
<P>Both groups received Calcium 1 gm/d</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Lunar DPA: lumbar spine, fractures side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score = 2<BR/>(R 1, B 0, W 1)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Ringe-1987">
<CHAR_METHODS>
<P>Randomized, open, controlled study<BR/>Treatment<BR/>Sample size at entry: SCT 19; C 19<BR/>Withdrawals: SCT 1; C 1<BR/>Trial duration: 6 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Thirty-six patients with steroid-dependent COPD<BR/>Mean age: SCT 49; C 50 years<BR/>Duration steroid use: SCT 67; C 75 months<BR/>Women/Men: SCT 15/3; C 14/4<BR/>Baseline prednisone mg/d: SCT 22.6; C 17.2<BR/>Prednisone dose during study mg/d: SCT 16.2; C 16.8<BR/>Lumbar BMD: unavailable</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Calcitonin 100 IU salmon calcitonin subcutaneously every other day versus control</P>
<P>Control group received analgesics on demand and physiotherapy</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Distal radius 1/3 and 1/10, nonvertebral and vertebral fractures, pain<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score = 2 <BR/>(R 1, B 0, W 1)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sambrook-1993">
<CHAR_METHODS>
<P>Double-blind randomized trial; <BR/>Prevention<BR/>Sample size at entry: SCT+D 29; D 34; Pl 29<BR/>Withdrawals: 11<BR/>Trial duration: 12 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>103 particpants newly started on steroids<BR/>Mean age: 52 years<BR/>Women/Men: SCT+D 23/6; D 27/7<BR/>Baseline calcium: SCT+D 810 mg/d; D 938 mg/d<BR/>Mean prednisone mg/d: 25 mg<BR/>Mean dose prednisone in first year: 13.5 mg/d<BR/>Mean dose prednisone in second year: 7.5 mg/d<BR/>Lumbar BMD: SCT+D 1.13; D 1.18</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Intranasal salmon calcitonin 400 IU per day plus calcitriol 0.5-1.0 ug/d<BR/>2. Calcitriol 0.5-1.0 ug plus placebo spray<BR/>3. Double placebo (placebo calcitriol and nasal spray)</P>
<P>All groups received calcium 1000 mg/d</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Lunar DPA: spine, femoral neck, distal radius, vertebral fractures, nonvertebral fractures, side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score = 3<BR/>(R 1, B 2, W 0)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Dottori-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Rheumatoid arthritis patients, not all taking corticosteroids</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Garcia_x002d_Delgado-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>No placebo. Randomized, comparative trial, Intranasal salmon calcitonin 100 IU/d versus cyclical etidronate vs calcifediol 32,000 IU/wk</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Montemurro-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>not an RCT, retrospective cohort design</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Bone mineral density</NAME>
<CONT_OUTCOME CHI2="4.09282567732345" CI_END="4.289282712781387" CI_START="1.3697585444697769" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="2.829520628625582" ESTIMABLE="YES" I2="2.268009552367609" I2_Q="0.0" ID="CMP-001.01" NO="1" P_CHI2="0.39358926878365563" P_Q="1.0" P_Z="1.452319676669255E-4" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.07344168091277448" TOTALS="YES" TOTAL_1="106" TOTAL_2="101" UNITS="" WEIGHT="99.99999999999999" Z="3.799083827298092">
<NAME>Lumbar spine - 6 months</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="6.1525167237051335" CI_START="-4.432516723705133" EFFECT_SIZE="0.8600000000000001" ESTIMABLE="YES" MEAN_1="-0.94" MEAN_2="-1.8" ORDER="16544" SD_1="7.42" SD_2="7.6" SE="2.7003132534331393" STUDY_ID="STD-Adachi-1997" TOTAL_1="16" TOTAL_2="15" WEIGHT="7.531601996697735"/>
<CONT_DATA CI_END="5.86702086118691" CI_START="-4.667020861186911" EFFECT_SIZE="0.6" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="-0.6" ORDER="16545" SD_1="10.41" SD_2="5.08" SE="2.6873049212804414" STUDY_ID="STD-Bohning-1990" TOTAL_1="19" TOTAL_2="17" WEIGHT="7.603958496569655"/>
<CONT_DATA CI_END="4.995289634447195" CI_START="0.8047103655528058" EFFECT_SIZE="2.9000000000000004" ESTIMABLE="YES" MEAN_1="3.2" MEAN_2="0.3" ORDER="16546" SD_1="4.0" SD_2="4.0" SE="1.0690449676496976" STUDY_ID="STD-Emkey-1995" TOTAL_1="28" TOTAL_2="28" WEIGHT="45.60659925218154"/>
<CONT_DATA CI_END="5.036561823998737" CI_START="-5.156561823998736" EFFECT_SIZE="-0.06" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="0.46" ORDER="16547" SD_1="9.0" SD_2="9.0" SE="2.6003344266526147" STUDY_ID="STD-Kotaniemi-1996" TOTAL_1="25" TOTAL_2="23" WEIGHT="8.11555020380481"/>
<CONT_DATA CI_END="7.061319583384678" CI_START="1.9386804166153224" EFFECT_SIZE="4.5" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="-1.5" ORDER="16548" SD_1="3.5" SD_2="4.3" SE="1.3068197189275106" STUDY_ID="STD-Ringe-1987" TOTAL_1="18" TOTAL_2="18" WEIGHT="31.14229005074625"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="22.842698939759064" CI_END="6.072094029157135" CI_START="0.26141390629543704" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="3.166753967726286" ESTIMABLE="YES" I2="78.11116797894138" I2_Q="0.0" ID="CMP-001.02" NO="2" P_CHI2="3.6175803782034777E-4" P_Q="1.0" P_Z="0.032653686182172834" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="9.751487317607648" TOTALS="YES" TOTAL_1="126" TOTAL_2="130" UNITS="" WEIGHT="100.0" Z="2.136315747350447">
<NAME>Lumbar spine - 1 year</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="7.4161658520382225" CI_START="-0.0961658520382227" EFFECT_SIZE="3.66" ESTIMABLE="YES" MEAN_1="-1.29" MEAN_2="-4.95" ORDER="16549" SD_1="6.76" SD_2="3.5" SE="1.9164463641507596" STUDY_ID="STD-Adachi-1997" TOTAL_1="16" TOTAL_2="15" WEIGHT="16.368451759175457"/>
<CONT_DATA CI_END="9.350625003779363" CI_START="-1.1506250037793633" EFFECT_SIZE="4.1" ESTIMABLE="YES" MEAN_1="-0.9" MEAN_2="-5.0" ORDER="16550" SD_1="10.65" SD_2="4.53" SE="2.678939534193293" STUDY_ID="STD-Bohning-1990" TOTAL_1="19" TOTAL_2="17" WEIGHT="12.98036396892241"/>
<CONT_DATA CI_END="1.5767518919759826" CI_START="-4.576751891975983" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="-1.3" MEAN_2="0.2" ORDER="16551" SD_1="4.2" SD_2="5.9" SE="1.5698002189045355" STUDY_ID="STD-Healey-1996" TOTAL_1="20" TOTAL_2="22" WEIGHT="17.987767681848307"/>
<CONT_DATA CI_END="8.385032999483581" CI_START="4.614967000516419" EFFECT_SIZE="6.5" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="-2.5" ORDER="16552" SD_1="2.5" SD_2="3.5" SE="0.9617692030835673" STUDY_ID="STD-Luengo-1990" TOTAL_1="20" TOTAL_2="20" WEIGHT="20.58113752283746"/>
<CONT_DATA CI_END="10.292615661814596" CI_START="0.7073843381854044" EFFECT_SIZE="5.5" ESTIMABLE="YES" MEAN_1="2.7" MEAN_2="-2.8" ORDER="16553" SD_1="8.11" SD_2="8.11" SE="2.4452570045256627" STUDY_ID="STD-Luengo-1994" TOTAL_1="22" TOTAL_2="22" WEIGHT="13.968436752694446"/>
<CONT_DATA CI_END="4.123208386984772" CI_START="-1.923208386984772" EFFECT_SIZE="1.1" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="-1.3" ORDER="16554" SD_1="6.5" SD_2="5.6" SE="1.5424816021271075" STUDY_ID="STD-Sambrook-1993" TOTAL_1="29" TOTAL_2="34" WEIGHT="18.11384231452191"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.11450317405136" CI_END="9.501149541416034" CI_START="-0.5635729905492388" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="4.468788275433398" ESTIMABLE="YES" I2="75.35277321234379" I2_Q="0.0" ID="CMP-001.03" NO="3" P_CHI2="0.01729655579242928" P_Q="1.0" P_Z="0.0817768629053268" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="14.557580294090961" TOTALS="YES" TOTAL_1="70" TOTAL_2="77" UNITS="" WEIGHT="100.0" Z="1.7404680648804876">
<NAME>Lumbar spine - 2 year</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.9475416369896696" CI_START="-3.7475416369896695" EFFECT_SIZE="0.1" ESTIMABLE="YES" MEAN_1="-0.1" MEAN_2="-0.2" ORDER="16555" SD_1="3.3" SD_2="8.3" SE="1.963067519270041" STUDY_ID="STD-Healey-1996" TOTAL_1="19" TOTAL_2="21" WEIGHT="35.806758313282046"/>
<CONT_DATA CI_END="16.881813130097306" CI_START="4.318186869902694" EFFECT_SIZE="10.6" ESTIMABLE="YES" MEAN_1="2.8" MEAN_2="-7.8" ORDER="16556" SD_1="10.63" SD_2="10.63" SE="3.205065592861627" STUDY_ID="STD-Luengo-1994" TOTAL_1="22" TOTAL_2="22" WEIGHT="26.550351183988"/>
<CONT_DATA CI_END="7.6695298688068885" CI_START="0.9304701311931112" EFFECT_SIZE="4.3" ESTIMABLE="YES" MEAN_1="0.7" MEAN_2="-3.6" ORDER="16557" SD_1="7.8" SD_2="5.4" SE="1.719179482574838" STUDY_ID="STD-Sambrook-1993" TOTAL_1="29" TOTAL_2="34" WEIGHT="37.642890502729955"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="6.334513872616853" CI_START="-4.0145138726168526" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.1600000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.04" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.6603889728774839" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="16" TOTAL_2="15" UNITS="" WEIGHT="100.0" Z="0.4393761961095449">
<NAME>Femoral neck - 6 months</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="6.334513872616853" CI_START="-4.0145138726168526" EFFECT_SIZE="1.1600000000000001" ESTIMABLE="YES" MEAN_1="-1.19" MEAN_2="-2.35" ORDER="16558" SD_1="8.35" SD_2="6.26" SE="2.6401066108524227" STUDY_ID="STD-Adachi-1997" TOTAL_1="16" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.7934845608388619" CI_END="0.2999378366497808" CI_START="-2.224023432093323" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.9620427977217713" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.05" NO="5" P_CHI2="0.6725075387695046" P_Q="1.0" P_Z="0.13514037898485287" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="65" TOTAL_2="71" UNITS="" WEIGHT="100.0" Z="1.4941348415063518">
<NAME>Femoral neck - 1 year</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.16567051090037754" CI_START="-2.605670510900377" EFFECT_SIZE="-1.2199999999999998" ESTIMABLE="YES" MEAN_1="-3.57" MEAN_2="-2.35" ORDER="16559" SD_1="2.14" SD_2="1.79" SE="0.7069877415250329" STUDY_ID="STD-Adachi-1997" TOTAL_1="16" TOTAL_2="15" WEIGHT="82.94408713742106"/>
<CONT_DATA CI_END="3.973888074218804" CI_START="-3.1738880742188043" EFFECT_SIZE="0.3999999999999999" ESTIMABLE="YES" MEAN_1="-2.9" MEAN_2="-3.3" ORDER="16560" SD_1="5.3" SD_2="6.5" SE="1.8234457890089701" STUDY_ID="STD-Healey-1996" TOTAL_1="20" TOTAL_2="22" WEIGHT="12.468766338691339"/>
<CONT_DATA CI_END="5.8922529725985076" CI_START="-5.8922529725985076" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="-2.8" MEAN_2="-2.8" ORDER="16561" SD_1="13.1" SD_2="10.3" SE="3.0063067582240524" STUDY_ID="STD-Sambrook-1993" TOTAL_1="29" TOTAL_2="34" WEIGHT="4.587146523887604"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.4152497872052199" CI_END="5.883183639409547" CI_START="-2.0226758554940636" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="1.9302538919577419" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.06" NO="6" P_CHI2="0.5193168919906936" P_Q="1.0" P_Z="0.33853223826580625" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="48" TOTAL_2="55" UNITS="" WEIGHT="100.0" Z="0.9570694019275809">
<NAME>Femoral neck - 2 year</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="8.726351454273656" CI_START="-2.326351454273657" EFFECT_SIZE="3.1999999999999997" ESTIMABLE="YES" MEAN_1="-3.6" MEAN_2="-6.8" ORDER="16562" SD_1="6.6" SD_2="10.9" SE="2.819618879665551" STUDY_ID="STD-Healey-1996" TOTAL_1="19" TOTAL_2="21" WEIGHT="51.16361122914393"/>
<CONT_DATA CI_END="6.256493922374938" CI_START="-5.056493922374939" EFFECT_SIZE="0.5999999999999996" ESTIMABLE="YES" MEAN_1="-3.2" MEAN_2="-3.8" ORDER="16563" SD_1="12.5" SD_2="10.0" SE="2.8860193182082123" STUDY_ID="STD-Sambrook-1993" TOTAL_1="29" TOTAL_2="34" WEIGHT="48.836388770856075"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.4233183118412542" CI_END="4.417860491020273" CI_START="1.414132669733461" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="2.915996580376867" ESTIMABLE="YES" I2="41.577153574004434" I2_Q="0.0" ID="CMP-001.07" NO="7" P_CHI2="0.18056623098929903" P_Q="1.0" P_Z="1.4155412557986308E-4" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.7409494513281714" TOTALS="YES" TOTAL_1="65" TOTAL_2="63" UNITS="" WEIGHT="100.0" Z="3.805436854882662">
<NAME>Distal radius - 6 months</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="7.80425741660107" CI_START="-0.4042574166010695" EFFECT_SIZE="3.7" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="-2.5" ORDER="16564" SD_1="6.15" SD_2="6.38" SE="2.094047364632681" STUDY_ID="STD-Bohning-1990" TOTAL_1="19" TOTAL_2="17" WEIGHT="11.454806311231726"/>
<CONT_DATA CI_END="3.204791539807137" CI_START="0.7952084601928633" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="2.4" MEAN_2="0.4" ORDER="16565" SD_1="2.3" SD_2="2.3" SE="0.614700856398576" STUDY_ID="STD-Emkey-1995" TOTAL_1="28" TOTAL_2="28" WEIGHT="52.4819500344719"/>
<CONT_DATA CI_END="5.846138573203918" CI_START="2.1538614267960816" EFFECT_SIZE="4.0" ESTIMABLE="YES" MEAN_1="2.6" MEAN_2="-1.4" ORDER="16566" SD_1="3.4" SD_2="2.1" SE="0.9419247433963194" STUDY_ID="STD-Ringe-1987" TOTAL_1="18" TOTAL_2="18" WEIGHT="36.063243654296365"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.31650554796122365" CI_END="6.739202794534579" CI_START="-0.6046161078413648" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="3.067293343346607" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.08" NO="8" P_CHI2="0.5737154095351893" P_Q="1.0" P_Z="0.10158104588462669" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="48" TOTAL_2="51" UNITS="" WEIGHT="100.0" Z="1.6372365830082791">
<NAME>Distal radius - 1 year</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="7.469308397952043" CI_START="-0.46930839795204315" EFFECT_SIZE="3.5" ESTIMABLE="YES" MEAN_1="-0.8" MEAN_2="-4.3" ORDER="16567" SD_1="5.83" SD_2="6.27" SE="2.025194559319172" STUDY_ID="STD-Bohning-1990" TOTAL_1="19" TOTAL_2="17" WEIGHT="85.57644477822024"/>
<CONT_DATA CI_END="10.168426548258724" CI_START="-9.168426548258724" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="1.3" MEAN_2="0.8" ORDER="16568" SD_1="24.1" SD_2="12.1" SE="4.9329613322091825" STUDY_ID="STD-Sambrook-1993" TOTAL_1="29" TOTAL_2="34" WEIGHT="14.423555221779772"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="13.380555514620614" CI_START="-9.380555514620614" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="2.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.09" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.7305147891476703" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="29" TOTAL_2="34" UNITS="" WEIGHT="100.0" Z="0.3444408283975393">
<NAME>Distal radius - 2 year</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="13.380555514620614" CI_START="-9.380555514620614" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="-1.6" MEAN_2="-3.6" ORDER="16569" SD_1="23.2" SD_2="22.7" SE="5.806512570837517" STUDY_ID="STD-Sambrook-1993" TOTAL_1="29" TOTAL_2="34" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="7.804713239062288" CI_END="15.316699116018949" CI_START="-5.228014484526799" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="5.044342315746075" ESTIMABLE="YES" I2="87.18722944239593" I2_Q="0.0" ID="CMP-001.10" NO="10" P_CHI2="0.005211029115319121" P_Q="1.0" P_Z="0.33581875829233676" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="48.061960230120754" TOTALS="YES" TOTAL_1="41" TOTAL_2="43" UNITS="" WEIGHT="100.0" Z="0.9624596825035373">
<NAME>Lumbar spine - 2 year - without Sambrook</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.9475416369896696" CI_START="-3.7475416369896695" EFFECT_SIZE="0.1" ESTIMABLE="YES" MEAN_1="-0.1" MEAN_2="-0.2" ORDER="16570" SD_1="3.3" SD_2="8.3" SE="1.963067519270041" STUDY_ID="STD-Healey-1996" TOTAL_1="19" TOTAL_2="21" WEIGHT="52.91102556432309"/>
<CONT_DATA CI_END="16.881813130097306" CI_START="4.318186869902694" EFFECT_SIZE="10.6" ESTIMABLE="YES" MEAN_1="2.8" MEAN_2="-7.8" ORDER="16571" SD_1="10.63" SD_2="10.63" SE="3.205065592861627" STUDY_ID="STD-Luengo-1994" TOTAL_1="22" TOTAL_2="22" WEIGHT="47.0889744356769"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Fractures</NAME>
<DICH_OUTCOME CHI2="2.605409407573579" CI_END="1.8878541989648228" CI_START="0.2640560988302069" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7060449100013939" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.27596845022151567" LOG_CI_START="-0.5783037972808956" LOG_EFFECT_SIZE="-0.15116767352968996" METHOD="MH" NO="1" P_CHI2="0.6258653104560186" P_Q="0.0" P_Z="0.48790140590909103" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="127" TOTAL_2="129" WEIGHT="99.99999999999999" Z="0.6936505232638146">
<NAME>Vertebral Fractures</NAME>
<GROUP_LABEL_1>Calcitonin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.348015821292505" CI_START="0.1123584229755981" EFFECT_SIZE="0.6133333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5247875016162632" LOG_CI_START="-0.9493943650365152" LOG_EFFECT_SIZE="-0.212303431710126" ORDER="16572" O_E="0.0" SE="0.8659417257897716" STUDY_ID="STD-Healey-1996" TOTAL_1="25" TOTAL_2="23" VAR="0.749855072463768" WEIGHT="33.58075575514401"/>
<DICH_DATA CI_END="7.645133861275818" CI_START="0.013666096196349616" EFFECT_SIZE="0.32323232323232326" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8833850940262291" LOG_CI_START="-1.8643555265815168" LOG_EFFECT_SIZE="-0.4904852162776439" ORDER="16573" O_E="0.0" SE="1.6140364420804247" STUDY_ID="STD-Kotaniemi-1996" TOTAL_1="32" TOTAL_2="31" VAR="2.6051136363636362" WEIGHT="9.665873952166724"/>
<DICH_DATA CI_END="6.480206230341023" CI_START="0.15431607644181022" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8115888273634806" LOG_CI_START="-0.8115888273634805" LOG_EFFECT_SIZE="0.0" ORDER="16574" O_E="0.0" SE="0.9534625892455924" STUDY_ID="STD-Luengo-1994" TOTAL_1="22" TOTAL_2="22" VAR="0.9090909090909092" WEIGHT="27.698770044177763"/>
<DICH_DATA CI_END="2.590192614031835" CI_START="0.00787901376706469" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.41333206064527345" LOG_CI_START="-2.1035281406737876" LOG_EFFECT_SIZE="-0.8450980400142568" ORDER="16575" O_E="0.0" SE="1.4784161409137435" STUDY_ID="STD-Ringe-1987" TOTAL_1="19" TOTAL_2="19" VAR="2.185714285714286" WEIGHT="11.520581717720995"/>
<DICH_DATA CI_END="24.556732044932673" CI_START="0.2238985382491653" EFFECT_SIZE="2.3448275862068964" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3901705713744927" LOG_CI_START="-0.6499487417599322" LOG_EFFECT_SIZE="0.3701109148072802" ORDER="16576" O_E="0.0" SE="1.1983761832886317" STUDY_ID="STD-Sambrook-1993" TOTAL_1="29" TOTAL_2="34" VAR="1.436105476673428" WEIGHT="17.534018530790497"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.230221277048346" CI_END="1.9632974917838897" CI_START="0.1401327373775217" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5245209736608241" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.292986111750345" LOG_CI_START="-0.8534603943249527" LOG_EFFECT_SIZE="-0.2802371412873038" METHOD="MH" NO="2" P_CHI2="0.5260203742323147" P_Q="0.0" P_Z="0.3379688043775856" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="102" TOTAL_2="106" WEIGHT="100.00000000000001" Z="0.9581863630669978">
<NAME>Nonvertebral fractures</NAME>
<GROUP_LABEL_1>Calcitonin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="68.80620475148235" CI_START="0.12299486576714651" EFFECT_SIZE="2.909090909090909" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8376276034655539" LOG_CI_START="-0.9101130171421922" LOG_EFFECT_SIZE="0.46375729316168096" ORDER="16577" O_E="0.0" SE="1.6140364420804247" STUDY_ID="STD-Kotaniemi-1996" TOTAL_1="32" TOTAL_2="31" VAR="2.6051136363636362" WEIGHT="17.408290365918305"/>
<DICH_DATA CI_END="15.000438199046616" CI_START="0.06666471917224105" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1761039460322296" LOG_CI_START="-1.1761039460322296" LOG_EFFECT_SIZE="0.0" ORDER="16578" O_E="0.0" SE="1.381698559415515" STUDY_ID="STD-Luengo-1994" TOTAL_1="22" TOTAL_2="22" VAR="1.9090909090909092" WEIGHT="23.755062895159355"/>
<DICH_DATA CI_END="1.5546741762656335" CI_START="0.02572886371347662" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.1916393848247231" LOG_CI_START="-1.5895793934967606" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="16579" O_E="0.0" SE="1.0462967275611939" STUDY_ID="STD-Ringe-1987" TOTAL_1="19" TOTAL_2="19" VAR="1.0947368421052632" WEIGHT="41.42600566070185"/>
<DICH_DATA CI_END="9.196087501391645" CI_START="0.01644553380754024" EFFECT_SIZE="0.3888888888888889" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9636030949581328" LOG_CI_START="-1.7839520251362313" LOG_EFFECT_SIZE="-0.41017446508904926" ORDER="16580" O_E="0.0" SE="1.6139274781606219" STUDY_ID="STD-Sambrook-1993" TOTAL_1="29" TOTAL_2="34" VAR="2.604761904761905" WEIGHT="17.4106410782205"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.6450475601240386" CI_END="1.9772546825694575" CI_START="0.2811631529572523" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7456079135515661" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.29606261271822476" LOG_CI_START="-0.5510415951595858" LOG_EFFECT_SIZE="-0.12748949122068054" METHOD="MH" NO="3" P_CHI2="0.6188644037314954" P_Q="0.0" P_Z="0.5552237825934456" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="109" TOTAL_2="113" WEIGHT="100.00000000000001" Z="0.5899505842990975">
<NAME>Vertebral fractures - efficacy</NAME>
<GROUP_LABEL_1>Calcitonin</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.9461656961121516" CI_START="0.13758578070443298" EFFECT_SIZE="0.7368421052631579" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5961753169517453" LOG_CI_START="-0.8614264475009272" LOG_EFFECT_SIZE="-0.13262556527459096" ORDER="16581" O_E="0.0" SE="0.8562024916845998" STUDY_ID="STD-Healey-1996" TOTAL_1="19" TOTAL_2="21" VAR="0.7330827067669172" WEIGHT="33.77504274999395"/>
<DICH_DATA CI_END="6.935322355152959" CI_START="0.012658603407767106" EFFECT_SIZE="0.2962962962962963" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8410666519717473" LOG_CI_START="-1.8976142063058348" LOG_EFFECT_SIZE="-0.5282737771670437" ORDER="16582" O_E="0.0" SE="1.6087146928411398" STUDY_ID="STD-Kotaniemi-1996" TOTAL_1="26" TOTAL_2="23" VAR="2.587962962962963" WEIGHT="9.567331571077148"/>
<DICH_DATA CI_END="6.303251334775796" CI_START="0.15864828274939313" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7995646244554626" LOG_CI_START="-0.7995646244554625" LOG_EFFECT_SIZE="0.0" ORDER="16583" O_E="0.0" SE="0.9393364366277243" STUDY_ID="STD-Luengo-1994" TOTAL_1="17" TOTAL_2="17" VAR="0.8823529411764706" WEIGHT="28.061219728378433"/>
<DICH_DATA CI_END="2.5811664393459135" CI_START="0.007906566176521997" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.41181600971974847" LOG_CI_START="-2.1020120897482624" LOG_EFFECT_SIZE="-0.8450980400142568" ORDER="16584" O_E="0.0" SE="1.4766350692772905" STUDY_ID="STD-Ringe-1987" TOTAL_1="18" TOTAL_2="18" VAR="2.1804511278195484" WEIGHT="11.355402303877279"/>
<DICH_DATA CI_END="24.556732044932673" CI_START="0.2238985382491653" EFFECT_SIZE="2.3448275862068964" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3901705713744927" LOG_CI_START="-0.6499487417599322" LOG_EFFECT_SIZE="0.3701109148072802" ORDER="16585" O_E="0.0" SE="1.1983761832886317" STUDY_ID="STD-Sambrook-1993" TOTAL_1="29" TOTAL_2="34" VAR="1.436105476673428" WEIGHT="17.24100364667319"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Toxicity</NAME>
<DICH_OUTCOME CHI2="2.6533446105077325" CI_END="2.3332441252332443" CI_START="0.5953346277358406" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1785843299113434" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.36796018101192324" LOG_CI_START="-0.2252388559041083" LOG_EFFECT_SIZE="0.07136066255390747" METHOD="MH" NO="1" P_CHI2="0.44821425672907855" P_Q="0.0" P_Z="0.6372412230274529" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="92" TOTAL_2="88" WEIGHT="100.0" Z="0.4715595266159301">
<NAME>Withdrawals</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.783918833890697" CI_START="0.4002342310399982" EFFECT_SIZE="1.875" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9436883141100868" LOG_CI_START="-0.3976857699826114" LOG_EFFECT_SIZE="0.27300127206373764" ORDER="16586" O_E="0.0" SE="0.7879297769048542" STUDY_ID="STD-Adachi-1997" TOTAL_1="16" TOTAL_2="15" VAR="0.6208333333333333" WEIGHT="19.55694668676707"/>
<DICH_DATA CI_END="12.329465069399493" CI_START="0.6178370235141931" EFFECT_SIZE="2.76" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.0909442345480729" LOG_CI_START="-0.2091260704176377" LOG_EFFECT_SIZE="0.4409090820652177" ORDER="16587" O_E="0.0" SE="0.7636677325886576" STUDY_ID="STD-Healey-1996" TOTAL_1="25" TOTAL_2="23" VAR="0.5831884057971014" WEIGHT="20.819351483458856"/>
<DICH_DATA CI_END="1.8529234864693696" CI_START="0.28489739066998254" EFFECT_SIZE="0.7265625" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.2678574861887238" LOG_CI_START="-0.5453115283765902" LOG_EFFECT_SIZE="-0.13872702109393326" ORDER="16588" O_E="0.0" SE="0.47765950440720595" STUDY_ID="STD-Kotaniemi-1996" TOTAL_1="32" TOTAL_2="31" VAR="0.2281586021505376" WEIGHT="53.215632840163245"/>
<DICH_DATA CI_END="14.848212018999854" CI_START="0.06734817624643254" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1716741602503453" LOG_CI_START="-1.1716741602503453" LOG_EFFECT_SIZE="0.0" ORDER="16589" O_E="0.0" SE="1.3764944032233706" STUDY_ID="STD-Ringe-1987" TOTAL_1="19" TOTAL_2="19" VAR="1.8947368421052633" WEIGHT="6.408068989610831"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.3029814275254252" CI_END="15.47009417609752" CI_START="0.655882709396079" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="3.1853676840878737" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" I2="9.172967943462437" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="1.1894929575283906" LOG_CI_START="-0.18317381796646778" LOG_EFFECT_SIZE="0.5031595697809614" METHOD="MH" NO="2" P_CHI2="0.3472279685368269" P_Q="0.0" P_Z="0.15075378435249331" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.23902159073333282" TOTALS="YES" TOTAL_1="98" TOTAL_2="96" WEIGHT="100.0" Z="1.4368740510847258">
<NAME>Withdrawals due to side effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="90.68889381830684" CI_START="0.24419008532721606" EFFECT_SIZE="4.705882352941177" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9575541046041152" LOG_CI_START="-0.6122719733767759" LOG_EFFECT_SIZE="0.6726410656136697" ORDER="16590" O_E="0.0" SE="1.5095285590502205" STUDY_ID="STD-Adachi-1997" TOTAL_1="16" TOTAL_2="15" VAR="2.2786764705882354" WEIGHT="25.82270908302848"/>
<DICH_DATA CI_END="7.645133861275818" CI_START="0.013666096196349616" EFFECT_SIZE="0.32323232323232326" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8833850940262291" LOG_CI_START="-1.8643555265815168" LOG_EFFECT_SIZE="-0.4904852162776439" ORDER="16591" O_E="0.0" SE="1.6140364420804247" STUDY_ID="STD-Kotaniemi-1996" TOTAL_1="32" TOTAL_2="31" VAR="2.6051136363636362" WEIGHT="22.85889361975652"/>
<DICH_DATA CI_END="251.76972362638108" CI_START="0.8936737776059743" EFFECT_SIZE="15.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.401003503164353" LOG_CI_START="-0.04882098505299036" LOG_EFFECT_SIZE="1.1760912590556813" ORDER="16592" O_E="0.0" SE="1.4390390312056631" STUDY_ID="STD-Luengo-1990" TOTAL_1="31" TOTAL_2="31" VAR="2.0708333333333333" WEIGHT="28.146263178273642"/>
<DICH_DATA CI_END="69.31319328145675" CI_START="0.1298454099994229" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8408159073966481" LOG_CI_START="-0.8865733979573234" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="16593" O_E="0.0" SE="1.6020819787597222" STUDY_ID="STD-Ringe-1987" TOTAL_1="19" TOTAL_2="19" VAR="2.566666666666667" WEIGHT="23.17213411894136"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.99043596806521" CI_END="18.423330414668456" CI_START="1.3575897104122003" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="5.001132252048333" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="2" I2="19.846682221818018" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="1.2653681410602229" LOG_CI_START="0.13276853767133323" LOG_EFFECT_SIZE="0.699068339365778" METHOD="MH" NO="4" P_CHI2="0.2882803006800452" P_Q="0.0" P_Z="0.015542887193975131" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.4435209179167878" TOTALS="YES" TOTAL_1="121" TOTAL_2="125" WEIGHT="100.00000000000001" Z="2.4194759803720234">
<NAME>Flushing or rash</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="126.23619543512021" CI_START="0.364992768358703" EFFECT_SIZE="6.787878787878788" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.101183897094496" LOG_CI_START="-0.43771574018194537" LOG_EFFECT_SIZE="0.8317340784562753" ORDER="16594" O_E="0.0" SE="1.4913622146920764" STUDY_ID="STD-Kotaniemi-1996" TOTAL_1="32" TOTAL_2="31" VAR="2.2241612554112553" WEIGHT="16.591816190210366"/>
<DICH_DATA CI_END="544.9154390413087" CI_START="2.2480552251468433" EFFECT_SIZE="35.0" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="0" LOG_CI_END="2.736329112905867" LOG_CI_START="0.35180697579468445" LOG_EFFECT_SIZE="1.5440680443502757" ORDER="16595" O_E="0.0" SE="1.4006801069140526" STUDY_ID="STD-Luengo-1990" TOTAL_1="20" TOTAL_2="20" VAR="1.9619047619047618" WEIGHT="18.400773154231658"/>
<DICH_DATA CI_END="98.52270194459342" CI_START="0.25374862348029537" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9935363136779938" LOG_CI_START="-0.5955963050059561" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="16596" O_E="0.0" SE="1.5208693166281149" STUDY_ID="STD-Luengo-1994" TOTAL_1="22" TOTAL_2="22" VAR="2.313043478260869" WEIGHT="16.05683231457771"/>
<DICH_DATA CI_END="126.47715552794979" CI_START="0.3874217426495779" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1020120897482624" LOG_CI_START="-0.4118160097197486" LOG_EFFECT_SIZE="0.8450980400142568" ORDER="16597" O_E="0.0" SE="1.4766350692772905" STUDY_ID="STD-Ringe-1987" TOTAL_1="18" TOTAL_2="18" VAR="2.1804511278195484" WEIGHT="16.86820267223507"/>
<DICH_DATA CI_END="7.809802775980644" CI_START="0.17600368942564215" EFFECT_SIZE="1.1724137931034482" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8926400666065174" LOG_CI_START="-0.7544782283199194" LOG_EFFECT_SIZE="0.069080919143299" ORDER="16598" O_E="0.0" SE="0.9675254398068446" STUDY_ID="STD-Sambrook-1993" TOTAL_1="29" TOTAL_2="34" VAR="0.936105476673428" WEIGHT="32.0823756687452"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7864753816698763" CI_END="46.536452488302025" CI_START="1.6070606511185535" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="8.647942046325142" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="1.6677932735902365" LOG_CI_START="0.206032267521934" LOG_EFFECT_SIZE="0.9369127705560852" METHOD="MH" NO="5" P_CHI2="0.674868523216176" P_Q="0.0" P_Z="0.011988932157031786" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="61" TOTAL_2="61" WEIGHT="100.0" Z="2.512469930887953">
<NAME>Nausea</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="305.877541470589" CI_START="1.1802108721823594" EFFECT_SIZE="19.0" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" LOG_CI_END="2.4855475908341154" LOG_CI_START="0.07195961107154199" LOG_EFFECT_SIZE="1.2787536009528289" ORDER="16599" O_E="0.0" SE="1.4177535267657217" STUDY_ID="STD-Luengo-1990" TOTAL_1="20" TOTAL_2="20" VAR="2.010025062656642" WEIGHT="36.67975923943022"/>
<DICH_DATA CI_END="69.86772125843243" CI_START="0.12881484951699032" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8442765789345066" LOG_CI_START="-0.8900340694951817" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="16600" O_E="0.0" SE="1.6061476099435992" STUDY_ID="STD-Luengo-1994" TOTAL_1="22" TOTAL_2="22" VAR="2.5797101449275357" WEIGHT="28.579658652130185"/>
<DICH_DATA CI_END="156.40839440296887" CI_START="0.5178750175729858" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.194260057835441" LOG_CI_START="-0.2857750389567913" LOG_EFFECT_SIZE="0.9542425094393249" ORDER="16601" O_E="0.0" SE="1.4567848922274773" STUDY_ID="STD-Ringe-1987" TOTAL_1="19" TOTAL_2="19" VAR="2.1222222222222227" WEIGHT="34.74058210843959"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.5519240031847867" CI_END="4.5734556318760236" CI_START="0.16075960779852153" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8574537501605138" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="35.563855063273316" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="0.6602444702528362" LOG_CI_START="-0.7938230620168631" LOG_EFFECT_SIZE="-0.06678929588201352" METHOD="MH" NO="6" P_CHI2="0.2128521166324311" P_Q="0.0" P_Z="0.8571109560519942" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.7131068558439433" TOTALS="YES" TOTAL_1="61" TOTAL_2="65" WEIGHT="100.0" Z="0.18005300520974124">
<NAME>GI symptoms</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.8843813103531986" CI_START="0.009683006254130959" EFFECT_SIZE="0.19393939393939394" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5893218558533486" LOG_CI_START="-2.013989787641349" LOG_EFFECT_SIZE="-0.7123339658940003" ORDER="16602" O_E="0.0" SE="1.5291981459892532" STUDY_ID="STD-Kotaniemi-1996" TOTAL_1="32" TOTAL_2="31" VAR="2.3384469696969696" WEIGHT="23.90690323620732"/>
<DICH_DATA CI_END="3.6131976384714566" CI_START="0.5178019717182865" EFFECT_SIZE="1.367816091954023" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.5578917177125068" LOG_CI_START="-0.28583630016468226" LOG_EFFECT_SIZE="0.13602770877391224" ORDER="16603" O_E="0.0" SE="0.49561001422210743" STUDY_ID="STD-Sambrook-1993" TOTAL_1="29" TOTAL_2="34" VAR="0.2456292861972375" WEIGHT="76.09309676379269"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.557275577367293" CI_START="0.5375072262154532" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1724137931034482" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-003.07" LOG_CI_END="0.4077775310303027" LOG_CI_START="-0.2696156927437046" LOG_EFFECT_SIZE="0.069080919143299" METHOD="MH" NO="7" P_CHI2="1.0" P_Q="0.0" P_Z="0.6893360014636928" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="29" TOTAL_2="34" WEIGHT="100.0" Z="0.3997563270132759">
<NAME>Nasal symptoms</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.557275577367293" CI_START="0.5375072262154532" EFFECT_SIZE="1.1724137931034482" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.4077775310303027" LOG_CI_START="-0.2696156927437046" LOG_EFFECT_SIZE="0.069080919143299" ORDER="16604" O_E="0.0" SE="0.3979041327953885" STUDY_ID="STD-Sambrook-1993" TOTAL_1="29" TOTAL_2="34" VAR="0.15832769889565018" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.730793044818325" CI_START="0.5033534507008611" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1724137931034482" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-003.08" LOG_CI_END="0.43628878805657373" LOG_CI_START="-0.29812694976997567" LOG_EFFECT_SIZE="0.069080919143299" METHOD="MH" NO="8" P_CHI2="1.0" P_Q="0.0" P_Z="0.7123380074414937" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="29" TOTAL_2="34" WEIGHT="100.0" Z="0.3687178979592259">
<NAME>Hypercalcemia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.730793044818325" CI_START="0.5033534507008611" EFFECT_SIZE="1.1724137931034482" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.43628878805657373" LOG_CI_START="-0.29812694976997567" LOG_EFFECT_SIZE="0.069080919143299" ORDER="16605" O_E="0.0" SE="0.4313994398158486" STUDY_ID="STD-Sambrook-1993" TOTAL_1="29" TOTAL_2="34" VAR="0.18610547667342797" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" NO="5">
<NAME>Prevention vs Treatment</NAME>
<CONT_OUTCOME CHI2="22.84269893975906" CI_END="6.212029197308914" CI_START="3.3506660807234825" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="4.781347639016198" ESTIMABLE="YES" I2="78.11116797894138" I2_Q="94.33214452695907" ID="CMP-005.01" NO="1" P_CHI2="3.617580378205698E-4" P_Q="2.6644607038828205E-5" P_Z="5.7455013952995086E-11" Q="17.643357434861986" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="9.751487317607646" TOTALS="SUB" TOTAL_1="126" TOTAL_2="130" UNITS="" WEIGHT="200.0" Z="6.550213159398269">
<NAME>Lumbar spine - 1 year</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.410858194200509" CI_END="3.7334311386909156" CI_START="-1.8716061098319021" DF="2" EFFECT_SIZE="0.9309125144295066" ESTIMABLE="YES" I2="54.65734984113425" ID="CMP-005.01.01" NO="1" P_CHI2="0.1102033225479373" P_Z="0.5150199156985059" STUDIES="3" TAU2="3.347832211629282" TOTAL_1="65" TOTAL_2="71" WEIGHT="100.0" Z="0.6510411689129487">
<NAME>Prevention</NAME>
<CONT_DATA CI_END="7.4161658520382225" CI_START="-0.0961658520382227" EFFECT_SIZE="3.66" ESTIMABLE="YES" MEAN_1="-1.29" MEAN_2="-4.95" ORDER="16606" SD_1="6.76" SD_2="3.5" SE="1.9164463641507596" STUDY_ID="STD-Adachi-1997" TOTAL_1="16" TOTAL_2="15" WEIGHT="29.122367125454385"/>
<CONT_DATA CI_END="1.5767518919759826" CI_START="-4.576751891975983" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="-1.3" MEAN_2="0.2" ORDER="16607" SD_1="4.2" SD_2="5.9" SE="1.5698002189045355" STUDY_ID="STD-Healey-1996" TOTAL_1="20" TOTAL_2="22" WEIGHT="35.17769553777407"/>
<CONT_DATA CI_END="4.123208386984772" CI_START="-1.923208386984772" EFFECT_SIZE="1.1" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="-1.3" ORDER="16608" SD_1="6.5" SD_2="5.6" SE="1.5424816021271075" STUDY_ID="STD-Sambrook-1993" TOTAL_1="29" TOTAL_2="34" WEIGHT="35.69993733677154"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.7884833106965641" CI_END="7.802304940815155" CI_START="4.474668952408667" DF="2" EFFECT_SIZE="6.138486946611911" ESTIMABLE="YES" I2="0.0" ID="CMP-005.01.02" NO="2" P_CHI2="0.6741913228790626" P_Z="4.791418474181338E-13" STUDIES="3" TAU2="0.0" TOTAL_1="61" TOTAL_2="59" WEIGHT="100.0" Z="7.2310874006925285">
<NAME>Treatment</NAME>
<CONT_DATA CI_END="9.350625003779363" CI_START="-1.1506250037793633" EFFECT_SIZE="4.1" ESTIMABLE="YES" MEAN_1="-0.9" MEAN_2="-5.0" ORDER="16609" SD_1="10.65" SD_2="4.53" SE="2.678939534193293" STUDY_ID="STD-Bohning-1990" TOTAL_1="19" TOTAL_2="17" WEIGHT="10.041292752067701"/>
<CONT_DATA CI_END="8.385032999483581" CI_START="4.614967000516419" EFFECT_SIZE="6.5" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="-2.5" ORDER="16610" SD_1="2.5" SD_2="3.5" SE="0.9617692030835673" STUDY_ID="STD-Luengo-1990" TOTAL_1="20" TOTAL_2="20" WEIGHT="77.90650451408582"/>
<CONT_DATA CI_END="10.292615661814596" CI_START="0.7073843381854044" EFFECT_SIZE="5.5" ESTIMABLE="YES" MEAN_1="2.7" MEAN_2="-2.8" ORDER="16611" SD_1="8.11" SD_2="8.11" SE="2.4452570045256627" STUDY_ID="STD-Luengo-1994" TOTAL_1="22" TOTAL_2="22" WEIGHT="12.052202733846471"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="2.3153848710341003" CI_END="1.9280346803499449" CI_START="0.2389091874236792" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6786937444879526" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="0.2851148414698992" LOG_CI_START="-0.6217671488240621" LOG_EFFECT_SIZE="-0.1683261536770815" METHOD="MH" NO="2" P_CHI2="0.6779694591964431" P_Q="0.0" P_Z="0.46687262381444716" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="124" TOTAL_2="120" WEIGHT="200.0" Z="0.7275769116471138">
<NAME>Vertebral fractures</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.9560018502276124" CI_END="2.720190018935587" CI_START="0.21836210820045296" DF="2" EFFECT_SIZE="0.7707051493538919" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" ID="CMP-005.02.01" LOG_CI_END="0.4345992427447691" LOG_CI_START="-0.6608227214030626" LOG_EFFECT_SIZE="-0.11311173932914681" NO="1" P_CHI2="0.6200216676381203" P_Z="0.6856493200825944" STUDIES="3" TAU2="0.0" TOTAL_1="84" TOTAL_2="80" WEIGHT="100.0" Z="0.4047662774157993">
<NAME>Prevention</NAME>
<DICH_DATA CI_END="3.348015821292505" CI_START="0.1123584229755981" EFFECT_SIZE="0.6133333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5247875016162632" LOG_CI_START="-0.9493943650365152" LOG_EFFECT_SIZE="-0.212303431710126" ORDER="16612" O_E="0.0" SE="0.8659417257897716" STUDY_ID="STD-Healey-1996" TOTAL_1="25" TOTAL_2="23" VAR="0.749855072463768" WEIGHT="55.215468273505316"/>
<DICH_DATA CI_END="7.5509007480259465" CI_START="0.013682649259775068" EFFECT_SIZE="0.32142857142857145" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8779987617700858" LOG_CI_START="-1.8638298055758746" LOG_EFFECT_SIZE="-0.49291552190289434" ORDER="16613" O_E="0.0" SE="1.6105636727293162" STUDY_ID="STD-Kotaniemi-1996" TOTAL_1="27" TOTAL_2="26" VAR="2.5939153439153437" WEIGHT="15.961815816569487"/>
<DICH_DATA CI_END="20.297315786482997" CI_START="0.18494594504461104" EFFECT_SIZE="1.9375" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.307438608543916" LOG_CI_START="-0.7329551861872201" LOG_EFFECT_SIZE="0.2872417111783479" ORDER="16614" O_E="0.0" SE="1.1985374151372459" STUDY_ID="STD-Sambrook-1993" TOTAL_1="32" TOTAL_2="31" VAR="1.436491935483871" WEIGHT="28.8227159099252"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2982442528530709" CI_END="3.3098129093514888" CI_START="0.07997775399382734" DF="1" EFFECT_SIZE="0.5145011201442687" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="22.97289221174197" ID="CMP-005.02.02" LOG_CI_END="0.5198034455181174" LOG_CI_START="-1.0970307962738075" LOG_EFFECT_SIZE="-0.2886136753778451" NO="2" P_CHI2="0.2545342995484915" P_Z="0.4840969490574514" STUDIES="2" TAU2="0.4607190782282571" TOTAL_1="40" TOTAL_2="40" WEIGHT="100.0" Z="0.6997283884331651">
<NAME>Treatment</NAME>
<DICH_DATA CI_END="6.480206230341023" CI_START="0.15431607644181022" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8115888273634806" LOG_CI_START="-0.8115888273634805" LOG_EFFECT_SIZE="0.0" ORDER="16615" O_E="0.0" SE="0.9534625892455924" STUDY_ID="STD-Luengo-1994" TOTAL_1="22" TOTAL_2="22" VAR="0.9090909090909092" WEIGHT="65.84849784138936"/>
<DICH_DATA CI_END="2.5811664393459135" CI_START="0.007906566176521997" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.41181600971974847" LOG_CI_START="-2.1020120897482624" LOG_EFFECT_SIZE="-0.8450980400142568" ORDER="16616" O_E="0.0" SE="1.4766350692772905" STUDY_ID="STD-Ringe-1987" TOTAL_1="18" TOTAL_2="18" VAR="2.1804511278195484" WEIGHT="34.15150215861063"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" NO="6">
<NAME>Low vs high quality</NAME>
<CONT_OUTCOME CHI2="22.84269893975906" CI_END="6.212029197308914" CI_START="3.3506660807234825" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="4.781347639016198" ESTIMABLE="YES" I2="78.11116797894138" I2_Q="94.33214452695907" ID="CMP-006.01" NO="1" P_CHI2="3.617580378205698E-4" P_Q="2.6644607038828205E-5" P_Z="5.7455013952995086E-11" Q="17.643357434861986" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="9.751487317607646" TOTALS="SUB" TOTAL_1="126" TOTAL_2="130" UNITS="" WEIGHT="200.0" Z="6.550213159398269">
<NAME>Lumbar spine - 1 year</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.788483310696564" CI_END="7.802304940815155" CI_START="4.474668952408667" DF="2" EFFECT_SIZE="6.138486946611911" ESTIMABLE="YES" I2="0.0" ID="CMP-006.01.01" NO="1" P_CHI2="0.6741913228790626" P_Z="4.791418474181338E-13" STUDIES="3" TAU2="0.0" TOTAL_1="61" TOTAL_2="59" WEIGHT="100.0" Z="7.2310874006925285">
<NAME>Quality &lt; 3</NAME>
<CONT_DATA CI_END="9.350625003779363" CI_START="-1.1506250037793633" EFFECT_SIZE="4.1" ESTIMABLE="YES" MEAN_1="-0.9" MEAN_2="-5.0" ORDER="16617" SD_1="10.65" SD_2="4.53" SE="2.678939534193293" STUDY_ID="STD-Bohning-1990" TOTAL_1="19" TOTAL_2="17" WEIGHT="10.041292752067701"/>
<CONT_DATA CI_END="8.385032999483581" CI_START="4.614967000516419" EFFECT_SIZE="6.5" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="-2.5" ORDER="16618" SD_1="2.5" SD_2="3.5" SE="0.9617692030835673" STUDY_ID="STD-Luengo-1990" TOTAL_1="20" TOTAL_2="20" WEIGHT="77.90650451408582"/>
<CONT_DATA CI_END="10.292615661814596" CI_START="0.7073843381854044" EFFECT_SIZE="5.5" ESTIMABLE="YES" MEAN_1="2.7" MEAN_2="-2.8" ORDER="16619" SD_1="8.11" SD_2="8.11" SE="2.4452570045256627" STUDY_ID="STD-Luengo-1994" TOTAL_1="22" TOTAL_2="22" WEIGHT="12.052202733846471"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.410858194200509" CI_END="3.7334311386909156" CI_START="-1.8716061098319021" DF="2" EFFECT_SIZE="0.9309125144295066" ESTIMABLE="YES" I2="54.65734984113425" ID="CMP-006.01.02" NO="2" P_CHI2="0.1102033225479373" P_Z="0.5150199156985059" STUDIES="3" TAU2="3.347832211629282" TOTAL_1="65" TOTAL_2="71" WEIGHT="100.0" Z="0.6510411689129487">
<NAME>Quality =&gt; 3</NAME>
<CONT_DATA CI_END="7.4161658520382225" CI_START="-0.0961658520382227" EFFECT_SIZE="3.66" ESTIMABLE="YES" MEAN_1="-1.29" MEAN_2="-4.95" ORDER="16620" SD_1="6.76" SD_2="3.5" SE="1.9164463641507596" STUDY_ID="STD-Adachi-1997" TOTAL_1="16" TOTAL_2="15" WEIGHT="29.122367125454385"/>
<CONT_DATA CI_END="1.5767518919759826" CI_START="-4.576751891975983" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="-1.3" MEAN_2="0.2" ORDER="16621" SD_1="4.2" SD_2="5.9" SE="1.5698002189045355" STUDY_ID="STD-Healey-1996" TOTAL_1="20" TOTAL_2="22" WEIGHT="35.17769553777407"/>
<CONT_DATA CI_END="4.123208386984772" CI_START="-1.923208386984772" EFFECT_SIZE="1.1" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="-1.3" ORDER="16622" SD_1="6.5" SD_2="5.6" SE="1.5424816021271075" STUDY_ID="STD-Sambrook-1993" TOTAL_1="29" TOTAL_2="34" WEIGHT="35.69993733677154"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="2.3153848710341003" CI_END="1.8227134895423935" CI_START="0.2551073054244204" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6818999390511064" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="0.26071840771710547" LOG_CI_START="-0.5932771044631796" LOG_EFFECT_SIZE="-0.16627934837303704" METHOD="MH" NO="2" P_CHI2="0.6779694591964431" P_Q="0.0" P_Z="0.4453206094939455" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="124" TOTAL_2="120" WEIGHT="200.0" Z="0.7632394539214888">
<NAME>Vertebral fractures</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.379629062273265" CI_END="2.0576641448091424" CI_START="0.12371485195829689" DF="2" EFFECT_SIZE="0.5045429764202041" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" I2="0.0" ID="CMP-006.02.01" LOG_CI_END="0.3133744899797597" LOG_CI_START="-0.9075781602225375" LOG_EFFECT_SIZE="-0.2971018351213889" NO="1" P_CHI2="0.5016691569266851" P_Z="0.3401545672467139" STUDIES="3" TAU2="0.0" TOTAL_1="67" TOTAL_2="66" WEIGHT="100.0" Z="0.9538599166514735">
<NAME>Quality &lt; 3</NAME>
<DICH_DATA CI_END="7.5509007480259465" CI_START="0.013682649259775068" EFFECT_SIZE="0.32142857142857145" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8779987617700858" LOG_CI_START="-1.8638298055758746" LOG_EFFECT_SIZE="-0.49291552190289434" ORDER="16623" O_E="0.0" SE="1.6105636727293162" STUDY_ID="STD-Kotaniemi-1996" TOTAL_1="27" TOTAL_2="26" VAR="2.5939153439153437" WEIGHT="19.829741355918713"/>
<DICH_DATA CI_END="6.480206230341023" CI_START="0.15431607644181022" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8115888273634806" LOG_CI_START="-0.8115888273634805" LOG_EFFECT_SIZE="0.0" ORDER="16624" O_E="0.0" SE="0.9534625892455924" STUDY_ID="STD-Luengo-1994" TOTAL_1="22" TOTAL_2="22" VAR="0.9090909090909092" WEIGHT="56.58033740588922"/>
<DICH_DATA CI_END="2.5811664393459135" CI_START="0.007906566176521997" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.41181600971974847" LOG_CI_START="-2.1020120897482624" LOG_EFFECT_SIZE="-0.8450980400142568" ORDER="16625" O_E="0.0" SE="1.4766350692772905" STUDY_ID="STD-Ringe-1987" TOTAL_1="18" TOTAL_2="18" VAR="2.1804511278195484" WEIGHT="23.589921238192066"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6070414809610901" CI_END="3.6015735780233324" CI_START="0.2299113985621607" DF="1" EFFECT_SIZE="0.9099685809674253" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" I2="0.0" ID="CMP-006.02.02" LOG_CI_END="0.5564922915833775" LOG_CI_START="-0.6384394967170974" LOG_EFFECT_SIZE="-0.04097360256685995" NO="2" P_CHI2="0.4359041014015127" P_Z="0.8930765290064689" STUDIES="2" TAU2="0.0" TOTAL_1="57" TOTAL_2="54" WEIGHT="100.0" Z="0.13441233404983222">
<NAME>Quality =&gt; 3</NAME>
<DICH_DATA CI_END="3.348015821292505" CI_START="0.1123584229755981" EFFECT_SIZE="0.6133333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5247875016162632" LOG_CI_START="-0.9493943650365152" LOG_EFFECT_SIZE="-0.212303431710126" ORDER="16626" O_E="0.0" SE="0.8659417257897716" STUDY_ID="STD-Healey-1996" TOTAL_1="25" TOTAL_2="23" VAR="0.749855072463768" WEIGHT="65.70283355121795"/>
<DICH_DATA CI_END="20.297315786482997" CI_START="0.18494594504461104" EFFECT_SIZE="1.9375" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.307438608543916" LOG_CI_START="-0.7329551861872201" LOG_EFFECT_SIZE="0.2872417111783479" ORDER="16627" O_E="0.0" SE="1.1985374151372459" STUDY_ID="STD-Sambrook-1993" TOTAL_1="32" TOTAL_2="31" VAR="1.436491935483871" WEIGHT="34.29716644878206"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" NO="7">
<NAME>Subgroup analysis for dosage</NAME>
<CONT_OUTCOME CHI2="22.842698939759067" CI_END="4.5798739688849315" CI_START="0.5781354425311296" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="2.5790047057080305" ESTIMABLE="YES" I2="78.11116797894138" I2_Q="54.65189560767442" ID="CMP-007.01" NO="1" P_CHI2="3.617580378205698E-4" P_Q="0.1375493652048636" P_Z="0.011527750845972205" Q="2.205163839592011" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="9.75148731760765" TOTALS="SUB" TOTAL_1="126" TOTAL_2="130" UNITS="" WEIGHT="200.0" Z="2.5262801684110636">
<NAME>Lumbar spine</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="19.09362648312398" CI_END="8.96950330537054" CI_START="-2.003498157355699" DF="2" EFFECT_SIZE="3.4830025740074206" ESTIMABLE="YES" I2="89.52530048826654" ID="CMP-007.01.01" NO="1" P_CHI2="7.142921107539113E-5" P_Z="0.21340886040707652" STUDIES="3" TAU2="20.56739751503866" TOTAL_1="62" TOTAL_2="64" WEIGHT="100.0" Z="1.2442465493700556">
<NAME>Calcitonin 50 - 100 IU</NAME>
<CONT_DATA CI_END="1.5767518919759826" CI_START="-4.576751891975983" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="-1.3" MEAN_2="0.2" ORDER="16628" SD_1="4.2" SD_2="5.9" SE="1.5698002189045355" STUDY_ID="STD-Healey-1996" TOTAL_1="20" TOTAL_2="22" WEIGHT="34.02273848235021"/>
<CONT_DATA CI_END="8.385032999483581" CI_START="4.614967000516419" EFFECT_SIZE="6.5" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="-2.5" ORDER="16629" SD_1="2.5" SD_2="3.5" SE="0.9617692030835673" STUDY_ID="STD-Luengo-1990" TOTAL_1="20" TOTAL_2="20" WEIGHT="36.459426777193514"/>
<CONT_DATA CI_END="10.292615661814596" CI_START="0.7073843381854044" EFFECT_SIZE="5.5" ESTIMABLE="YES" MEAN_1="2.7" MEAN_2="-2.8" ORDER="16630" SD_1="8.11" SD_2="8.11" SE="2.4452570045256627" STUDY_ID="STD-Luengo-1994" TOTAL_1="22" TOTAL_2="22" WEIGHT="29.517834740456273"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.5439086170430767" CI_END="4.589194238617678" CI_START="0.29146779438327375" DF="2" EFFECT_SIZE="2.4403310165004757" ESTIMABLE="YES" I2="0.0" ID="CMP-007.01.02" NO="2" P_CHI2="0.4621092158025789" P_Z="0.026026921496052777" STUDIES="3" TAU2="0.0" TOTAL_1="64" TOTAL_2="66" WEIGHT="100.0" Z="2.2258098391131957">
<NAME>Calcitonin 200-400 IU</NAME>
<CONT_DATA CI_END="7.4161658520382225" CI_START="-0.0961658520382227" EFFECT_SIZE="3.66" ESTIMABLE="YES" MEAN_1="-1.29" MEAN_2="-4.95" ORDER="16631" SD_1="6.76" SD_2="3.5" SE="1.9164463641507596" STUDY_ID="STD-Adachi-1997" TOTAL_1="16" TOTAL_2="15" WEIGHT="32.72864502033115"/>
<CONT_DATA CI_END="9.350625003779363" CI_START="-1.1506250037793633" EFFECT_SIZE="4.1" ESTIMABLE="YES" MEAN_1="-0.9" MEAN_2="-5.0" ORDER="16632" SD_1="10.65" SD_2="4.53" SE="2.678939534193293" STUDY_ID="STD-Bohning-1990" TOTAL_1="19" TOTAL_2="17" WEIGHT="16.749256799333267"/>
<CONT_DATA CI_END="4.123208386984772" CI_START="-1.923208386984772" EFFECT_SIZE="1.1" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="-1.3" ORDER="16633" SD_1="6.5" SD_2="5.6" SE="1.5424816021271075" STUDY_ID="STD-Sambrook-1993" TOTAL_1="29" TOTAL_2="34" WEIGHT="50.52209818033559"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="2.605409407573579" CI_END="1.8878541989648228" CI_START="0.2640560988302069" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7060449100013939" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-007.02" LOG_CI_END="0.27596845022151567" LOG_CI_START="-0.5783037972808956" LOG_EFFECT_SIZE="-0.15116767352968996" METHOD="MH" NO="2" P_CHI2="0.6258653104560186" P_Q="0.0" P_Z="0.4879014059090909" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="127" TOTAL_2="129" WEIGHT="200.00000000000003" Z="0.6936505232638147">
<NAME>Vertebral fractures</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.3982915914564986" CI_END="1.6156817197553512" CI_START="0.18519917636630112" DF="3" EFFECT_SIZE="0.5470127272457013" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" I2="0.0" ID="CMP-007.02.01" LOG_CI_END="0.2083558112850631" LOG_CI_START="-0.7323609490815463" LOG_EFFECT_SIZE="-0.26200256889824164" NO="1" P_CHI2="0.7059354550693304" P_Z="0.27494130109840187" STUDIES="4" TAU2="0.0" TOTAL_1="98" TOTAL_2="95" WEIGHT="100.00000000000001" Z="1.091753906239332">
<NAME>Calcitonin 50 - 100 IU</NAME>
<DICH_DATA CI_END="3.348015821292505" CI_START="0.1123584229755981" EFFECT_SIZE="0.6133333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5247875016162632" LOG_CI_START="-0.9493943650365152" LOG_EFFECT_SIZE="-0.212303431710126" ORDER="16634" O_E="0.0" SE="0.8659417257897716" STUDY_ID="STD-Healey-1996" TOTAL_1="25" TOTAL_2="23" VAR="0.749855072463768" WEIGHT="40.72073739604025"/>
<DICH_DATA CI_END="7.645133861275818" CI_START="0.013666096196349616" EFFECT_SIZE="0.32323232323232326" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8833850940262291" LOG_CI_START="-1.8643555265815168" LOG_EFFECT_SIZE="-0.4904852162776439" ORDER="16635" O_E="0.0" SE="1.6140364420804247" STUDY_ID="STD-Kotaniemi-1996" TOTAL_1="32" TOTAL_2="31" VAR="2.6051136363636362" WEIGHT="11.721043974691181"/>
<DICH_DATA CI_END="6.480206230341023" CI_START="0.15431607644181022" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8115888273634806" LOG_CI_START="-0.8115888273634805" LOG_EFFECT_SIZE="0.0" ORDER="16636" O_E="0.0" SE="0.9534625892455924" STUDY_ID="STD-Luengo-1994" TOTAL_1="22" TOTAL_2="22" VAR="0.9090909090909092" WEIGHT="33.58811663997441"/>
<DICH_DATA CI_END="2.590192614031835" CI_START="0.00787901376706469" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.41333206064527345" LOG_CI_START="-2.1035281406737876" LOG_EFFECT_SIZE="-0.8450980400142568" ORDER="16637" O_E="0.0" SE="1.4784161409137435" STUDY_ID="STD-Ringe-1987" TOTAL_1="19" TOTAL_2="19" VAR="2.185714285714286" WEIGHT="13.97010198929417"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="24.556732044932673" CI_START="0.2238985382491653" DF="0" EFFECT_SIZE="2.3448275862068964" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-007.02.02" LOG_CI_END="1.3901705713744927" LOG_CI_START="-0.6499487417599322" LOG_EFFECT_SIZE="0.3701109148072802" NO="2" P_CHI2="1.0" P_Z="0.476998195212629" STUDIES="1" TAU2="0.0" TOTAL_1="29" TOTAL_2="34" WEIGHT="100.00000000000001" Z="0.7111388619648288">
<NAME>Calcitonin 200 - 400 IU</NAME>
<DICH_DATA CI_END="24.556732044932673" CI_START="0.2238985382491653" EFFECT_SIZE="2.3448275862068964" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3901705713744927" LOG_CI_START="-0.6499487417599322" LOG_EFFECT_SIZE="0.3701109148072802" ORDER="16638" O_E="0.0" SE="1.1983761832886317" STUDY_ID="STD-Sambrook-1993" TOTAL_1="29" TOTAL_2="34" VAR="1.436105476673428" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" NO="8">
<NAME>Route of administration: intranasal vs subcutaneous</NAME>
<CONT_OUTCOME CHI2="22.84269893975906" CI_END="6.427175705136735" CI_START="3.414093210375496" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="4.920634457756115" ESTIMABLE="YES" I2="78.11116797894138" I2_Q="92.99426407337144" ID="CMP-008.01" NO="1" P_CHI2="3.617580378205698E-4" P_Q="1.5803260114888307E-4" P_Z="1.5376249182885952E-10" Q="14.274017897235233" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="9.751487317607646" TOTALS="SUB" TOTAL_1="126" TOTAL_2="130" UNITS="" WEIGHT="200.0" Z="6.40159460290714">
<NAME>Lumbar spine - 1 year</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="8.568681042523828" CI_END="4.634694070839122" CI_START="-0.378345182492164" DF="4" EFFECT_SIZE="2.128174444173479" ESTIMABLE="YES" I2="53.31836976835543" ID="CMP-008.01.01" NO="1" P_CHI2="0.07283266763373497" P_Z="0.09608878402631964" STUDIES="5" TAU2="4.247877754715028" TOTAL_1="106" TOTAL_2="110" WEIGHT="100.0" Z="1.6641183332553162">
<NAME>Intranasal</NAME>
<CONT_DATA CI_END="7.4161658520382225" CI_START="-0.0961658520382227" EFFECT_SIZE="3.66" ESTIMABLE="YES" MEAN_1="-1.29" MEAN_2="-4.95" ORDER="16639" SD_1="6.76" SD_2="3.5" SE="1.9164463641507596" STUDY_ID="STD-Adachi-1997" TOTAL_1="16" TOTAL_2="15" WEIGHT="20.648357936967265"/>
<CONT_DATA CI_END="9.350625003779363" CI_START="-1.1506250037793633" EFFECT_SIZE="4.1" ESTIMABLE="YES" MEAN_1="-0.9" MEAN_2="-5.0" ORDER="16640" SD_1="10.65" SD_2="4.53" SE="2.678939534193293" STUDY_ID="STD-Bohning-1990" TOTAL_1="19" TOTAL_2="17" WEIGHT="14.315457503449013"/>
<CONT_DATA CI_END="1.5767518919759826" CI_START="-4.576751891975983" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="-1.3" MEAN_2="0.2" ORDER="16641" SD_1="4.2" SD_2="5.9" SE="1.5698002189045355" STUDY_ID="STD-Healey-1996" TOTAL_1="20" TOTAL_2="22" WEIGHT="24.36600632584425"/>
<CONT_DATA CI_END="10.292615661814596" CI_START="0.7073843381854044" EFFECT_SIZE="5.5" ESTIMABLE="YES" MEAN_1="2.7" MEAN_2="-2.8" ORDER="16642" SD_1="8.11" SD_2="8.11" SE="2.4452570045256627" STUDY_ID="STD-Luengo-1994" TOTAL_1="22" TOTAL_2="22" WEIGHT="15.991566371718115"/>
<CONT_DATA CI_END="4.123208386984772" CI_START="-1.923208386984772" EFFECT_SIZE="1.1" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="-1.3" ORDER="16643" SD_1="6.5" SD_2="5.6" SE="1.5424816021271075" STUDY_ID="STD-Sambrook-1993" TOTAL_1="29" TOTAL_2="34" WEIGHT="24.678611862021356"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="8.385032999483581" CI_START="4.614967000516419" DF="0" EFFECT_SIZE="6.5" ESTIMABLE="YES" I2="0.0" ID="CMP-008.01.02" NO="2" P_CHI2="1.0" P_Z="1.3954490176408712E-11" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="6.758378183830472">
<NAME>Subcutaneous injection</NAME>
<CONT_DATA CI_END="8.385032999483581" CI_START="4.614967000516419" EFFECT_SIZE="6.5" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="-2.5" ORDER="16644" SD_1="2.5" SD_2="3.5" SE="0.9617692030835673" STUDY_ID="STD-Luengo-1990" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="2.6054094075735783" CI_END="1.8878541989648228" CI_START="0.2640560988302069" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7060449100013939" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-008.02" LOG_CI_END="0.27596845022151567" LOG_CI_START="-0.5783037972808956" LOG_EFFECT_SIZE="-0.15116767352968996" METHOD="MH" NO="2" P_CHI2="0.6258653104560186" P_Q="0.0" P_Z="0.4879014059090909" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="127" TOTAL_2="129" WEIGHT="200.0" Z="0.6936505232638147">
<NAME>Vertebral fractures</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.2451390926870998" CI_END="2.473317360832851" CI_START="0.30555759372874947" DF="3" EFFECT_SIZE="0.8693335960973941" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" I2="0.0" ID="CMP-008.02.01" LOG_CI_END="0.3932798459267958" LOG_CI_START="-0.5149069187073271" LOG_EFFECT_SIZE="-0.060813536390265585" NO="1" P_CHI2="0.7421997637203177" P_Z="0.7929481603463491" STUDIES="4" TAU2="0.0" TOTAL_1="108" TOTAL_2="110" WEIGHT="100.00000000000001" Z="0.2624842064186104">
<NAME>Intranasal</NAME>
<DICH_DATA CI_END="3.348015821292505" CI_START="0.1123584229755981" EFFECT_SIZE="0.6133333333333333" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5247875016162632" LOG_CI_START="-0.9493943650365152" LOG_EFFECT_SIZE="-0.212303431710126" ORDER="16645" O_E="0.0" SE="0.8659417257897716" STUDY_ID="STD-Healey-1996" TOTAL_1="25" TOTAL_2="23" VAR="0.749855072463768" WEIGHT="37.953183245407594"/>
<DICH_DATA CI_END="7.645133861275818" CI_START="0.013666096196349616" EFFECT_SIZE="0.32323232323232326" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8833850940262291" LOG_CI_START="-1.8643555265815168" LOG_EFFECT_SIZE="-0.4904852162776439" ORDER="16646" O_E="0.0" SE="1.6140364420804247" STUDY_ID="STD-Kotaniemi-1996" TOTAL_1="32" TOTAL_2="31" VAR="2.6051136363636362" WEIGHT="10.924432076767669"/>
<DICH_DATA CI_END="6.480206230341023" CI_START="0.15431607644181022" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8115888273634806" LOG_CI_START="-0.8115888273634805" LOG_EFFECT_SIZE="0.0" ORDER="16647" O_E="0.0" SE="0.9534625892455924" STUDY_ID="STD-Luengo-1994" TOTAL_1="22" TOTAL_2="22" VAR="0.9090909090909092" WEIGHT="31.30532566998735"/>
<DICH_DATA CI_END="24.556732044932673" CI_START="0.2238985382491653" EFFECT_SIZE="2.3448275862068964" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3901705713744927" LOG_CI_START="-0.6499487417599322" LOG_EFFECT_SIZE="0.3701109148072802" ORDER="16648" O_E="0.0" SE="1.1983761832886317" STUDY_ID="STD-Sambrook-1993" TOTAL_1="29" TOTAL_2="34" VAR="1.436105476673428" WEIGHT="19.817059007837397"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.590192614031835" CI_START="0.00787901376706469" DF="0" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" ID="CMP-008.02.02" LOG_CI_END="0.41333206064527345" LOG_CI_START="-2.1035281406737876" LOG_EFFECT_SIZE="-0.8450980400142568" NO="2" P_CHI2="1.0" P_Z="0.1881026512600156" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="19" WEIGHT="100.0" Z="1.316212732805144">
<NAME>Subcutaneous injection</NAME>
<DICH_DATA CI_END="2.590192614031835" CI_START="0.00787901376706469" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.41333206064527345" LOG_CI_START="-2.1035281406737876" LOG_EFFECT_SIZE="-0.8450980400142568" ORDER="16649" O_E="0.0" SE="1.4784161409137435" STUDY_ID="STD-Ringe-1987" TOTAL_1="19" TOTAL_2="19" VAR="2.185714285714286" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>